Combined aqueous humor shunt for glaucoma treatment (aqueous shunt)

JP2024069527A5Active Publication Date: 2024-11-26WL GORE & ASSOC INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024042019
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-03-15
Filing Date
2024-03-18
Publication Date
2024-11-26
Estimated Expiration
2038-03-16

AI Technical Summary

Technical Problem

Conventional glaucoma devices lack flexibility, conformability, and tissue adhesion, leading to relative movement between the device and surrounding tissue, causing irritation, chronic inflammatory reactions, excessive scarring, and increased risk of device erosion and endophthalmitis, which inhibits proper functioning and exacerbates intraocular pressure.

Method used

A biofluidic drainage device with a stacked configuration of microporous membranes, including expandable reservoirs and fluid conduits, designed to allow tissue ingrowth and minimize adhesion, using materials like expanded polytetrafluorocarbon to resist tissue ingrowth and promote biointegration, reducing relative movement and irritation.

Benefits of technology

The device effectively stabilizes intraocular pressure by allowing tissue integration, minimizing irritation and scarring, and preventing device erosion, thus maintaining functionality and reducing complications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

To provide a glaucoma treatment device.SOLUTION: A glaucoma treatment device includes a plurality of microporous layers arranged together so as to form a microporous body configured to facilitate an evacuation of fluid from a fluid-filled body cavity and reabsorption of drained aqueous humor by the body through tissue surrounding the glaucoma treatment device. In some examples, the glaucoma treatment device includes one or more portions configured to resist cellular internal growth and one or more portions configured to allow the cellular internal growth. Especially, the outside thereof may comprise or be defined by one or more membranes, where the membranes are porous or otherwise permeable to the fluid of the fluid-filled body cavity.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] background Aqueous humor is the fluid that fills the anterior chamber of the eye and contributes to intraocular pressure, or fluid pressure within the eye. Glaucoma is a progressive eye disease characterized by an increase in intraocular pressure. This increase in intraocular pressure is usually caused by an insufficient amount of aqueous humor being reabsorbed by the body. In some cases, aqueous humor is not absorbed quickly enough or at all, and in other cases, aqueous humor is additionally or alternatively produced too quickly. Increased intraocular pressure is associated with gradual and sometimes permanent vision loss in the affected eye.

[0002] Many attempts have been made to treat glaucoma. However, some of the conventional devices lack the flexibility, conformability and device / tissue adhesion required to avoid relative movement between the device and the surrounding tissue. Such movement can lead to persistent irritation of the surrounding tissue. Irritation can then lead to increased chronic inflammatory tissue reaction, excessive scarring at the device site and increased risk of device erosion through the conjunctiva and endophthalmitis. In the absence of erosion, scar tissue effectively inhibits reabsorption of aqueous humor. These complications can act to inhibit the proper functioning of the device. The resulting effect is a gradual increase in intraocular pressure and progression of glaucoma. Summary of the Invention

[0003] According to one example ("Example 1"), a biological fluid drainage device includes a body including a first microporous membrane, a second microporous membrane, a third microporous membrane, and a fourth microporous membrane in a stacked configuration, the second and third microporous membranes disposed between the first and fourth microporous membranes, and an expandable reservoir defined between the second and third microporous membranes, where the second and third microporous membranes are configured to resist tissue ingrowth and the first and fourth microporous membranes are configured to allow tissue ingrowth, a fluid conduit having a first end and a second end, the first end fluidly coupled to the reservoir and the second end extending outside the body, and insertable into a fluid-filled body cavity such that fluid from the fluid-filled body cavity can be transferred to the reservoir.

[0004] In addition to Example 1, according to another example ("Example 2"), the second and third microporous membranes are partially bonded to one another such that portions of the second and third microporous membranes are free to slide relative to one another or separate from one another.

[0005] According to another example ("Example 3"), in addition to either of Examples 1 and 2, the second and third microporous membranes each have a different permeability than the permeability of each of the first and fourth microporous membranes.

[0006] According to another example ("Example 4"), in addition to any of Examples 1-3, at least one of the first, second, third and fourth microporous membranes comprises expanded polytetrafluoroethylene.

[0007] In addition to any of the above examples, according to another example ("Example 5"), the fluid is aqueous humor and the fluid-filled cavity is the anterior chamber.

[0008] In addition to any of the above examples, according to another example ("Example 6"), the device further includes a fifth microporous membrane disposed adjacent to the body, the fifth microporous membrane extending between the body and a second end of the fluid conduit.

[0009] In addition to Example 6, according to another example ("Example 7"), the fifth microporous membrane is configured to permit tissue ingrowth.

[0010] According to another example ("Example 8"), in addition to any of Examples 6-7, the fifth microporous membrane is bonded to the fluid conduit.

[0011] According to another example ("Example 9"), in addition to any of Examples 6-8, the fifth microporous membrane is integral with one of the first, second, third or fourth microporous membranes.

[0012] In addition to Example 9, according to another example ("Example 10"), the fifth microporous membrane and the first microporous membrane are the same microporous membrane.

[0013] According to another example ("Example 11"), in addition to any of Examples 6-10, the device further includes a sixth microporous membrane disposed adjacent to the body, the sixth microporous membrane extending between the body and the second end of the fluid conduit.

[0014] In addition to Example 11, according to another example ("Example 12"), the sixth microporous membrane and the fourth microporous membrane are the same microporous membrane.

[0015] According to another example ("Example 13") in addition to any of Examples 11-12, the sixth microporous membrane includes perforations sized to accommodate a fluid conduit such that, upon implantation, the fluid conduit can be extended through the perforations into a fluid-filled body cavity.

[0016] In addition to any of the above examples, according to another example ("Example 14"), the first and fourth microporous membranes are configured to remain permeable to the fluid after tissue ingrowth occurs in the first and fourth microporous membranes, respectively.

[0017] In addition to any of the above examples, according to another example ("Example 15"), the reservoir is configured to expand when the fluid is transferred to the reservoir.

[0018] In addition to Example 15, according to another example ("Example 16"), the body is configured to adopt a predetermined profile as a result of expansion of the reservoir.

[0019] In addition to any of the above examples, according to another example ("Example 17"), the first, second, third and fourth microporous membranes each comprise a plurality of pores, wherein the plurality of pores of the second and third microporous membranes are sized to resist tissue ingrowth and the plurality of pores of the first and fourth microporous membranes are sized to permit tissue ingrowth.

[0020] In addition to any of the above examples, according to another example ("Example 18"), one of the second and third microporous membranes is hydrophobic and one of the first and fourth microporous membranes is hydrophilic. In addition to any of the above examples, according to another example, the first, second, third and fourth microporous membranes are hydrophobic. In addition to any of the above examples, according to another example, the first, second, third and fourth microporous membranes are hydrophilic.

[0021] In addition to any of the above examples, according to another example ("Example 19"), one of the first, second, third, and fourth microporous membranes is formed from a plurality of microporous layers of expanded polytetrafluoroethylene.

[0022] According to another example ("Example 20"), an aqueous humor diffusion device includes a first proliferative diffusion membrane configured to permit tissue ingrowth, a first constrictive diffusion membrane configured to resist tissue ingrowth, the first constrictive diffusion membrane bonded to the first proliferative diffusion membrane, a second constrictive diffusion membrane configured to resist tissue ingrowth, bonded to the first constrictive diffusion membrane such that a first region of the second constrictive diffusion membrane is bonded to the first constrictive diffusion membrane and a second portion of the second constrictive diffusion membrane is unbonded from the first constrictive diffusion membrane, the second unbonded region defining an expandable reservoir, and a second proliferative diffusion membrane configured to permit tissue ingrowth, the second constrictive diffusion membrane bonded to the second constrictive diffusion membrane.

[0023] In addition to Example 20, according to another example (Example 21), the first and second proliferative diffusion membranes include a plurality of pores configured to permit tissue ingrowth, and the first and second constrictive diffusion membranes include a plurality of pores configured to resist tissue ingrowth.

[0024] In addition to any of Examples 20 to 22, according to another example ("Example 22"), the first region of the second constricting diffusion membrane is a peripheral region of the second constricting diffusion membrane, the first region of the second constricting diffusion membrane is bonded to the peripheral region of the first constricting diffusion membrane, and the second region of the second constricting diffusion membrane is a region inside the peripheral region of the second constricting diffusion membrane.

[0025] According to another example ("Example 23") in addition to any of Examples 20-22, the device further includes a fluid conduit having a first end and a second end, the first end being in fluid communication with the reservoir and the second end extending away from the first and second constricting diffusion membranes, and insertable into a fluid-filled body cavity such that fluid from the fluid-filled body cavity can be transferred to the reservoir.

[0026] In addition to Example 23, according to another example ("Example 24"), the device further includes a third proliferative diffusion membrane including a plurality of pores sized to permit tissue ingrowth, the third proliferative diffusion membrane disposed adjacent to the first proliferative diffusion membrane and extending along the fluid conduit between the first proliferative diffusion membrane and a second end of the fluid conduit.

[0027] In addition to Example 24, according to another example ("Example 25"), the third proliferative membrane and the first proliferative diffusion membrane are the same proliferative diffusion membrane.

[0028] According to another example ("Example 26") in addition to any of Examples 24-25, the third proliferative diffusion membrane is bonded to the fluid conduit.

[0029] According to another example ("Example 27") in addition to any of Examples 23-26, the device further includes a fourth proliferative diffusion membrane including a plurality of pores sized to permit tissue ingrowth, the fourth proliferative diffusion membrane being positioned adjacent to the second proliferative diffusion membrane and extending along the fluid conduit between the second proliferative diffusion membrane and a second end of the fluid conduit.

[0030] In addition to Example 27, according to another example ("Example 28"), the fourth proliferative membrane and the second proliferative diffusion membrane are the same proliferative membrane.

[0031] According to another example ("Example 29") in addition to any of Examples 27-28, the fourth proliferative diffusion membrane includes perforations sized to accommodate fluid conduits such that, upon implantation, the fluid conduits extend through the perforations into a fluid-filled body cavity.

[0032] In addition to any of Examples 20-29, according to another example ("Example 30"), the fluid-filled body cavity is the anterior chamber of a patient's eye, and the fluid is aqueous humor.

[0033] According to another example ("Example 31"), a method of forming a glaucoma drainage device includes providing a first proliferative diffusion membrane and a second proliferative diffusion membrane, each of the first and second proliferative diffusion membranes configured to permit tissue ingrowth; providing a first constricting diffusion membrane and a second constricting diffusion membrane, each of the first and second constricting diffusion membranes configured to resist tissue ingrowth; bonding the first proliferative diffusion membrane to the first constricting diffusion membrane; bonding the first constricting diffusion membrane to the second constricting diffusion membrane such that a first region of a first interface surface of the second constricting diffusion membrane is bonded to the first constricting diffusion membrane and a second region of the first interface surface is not bonded to the first constricting diffusion membrane, wherein the unbonded second region defines an expandable reservoir; and forming an aqueous humor diffusion member by bonding the second proliferative diffusion membrane to the second constricting diffusion membrane. The method further includes coupling a fluid conduit to the aqueous humor diffusing member such that the fluid conduit is fluidly coupled to the reservoir such that the conduit is operable to deliver the drained aqueous humor to the reservoir.

[0034] In addition to Example 31, according to another example (Example 32), the aqueous humor diffusing member further includes a third proliferative diffusion membrane configured to allow tissue ingrowth, the third proliferative membrane being positioned adjacent to the first proliferative diffusion membrane and extending along the fluid conduit.

[0035] In addition to Example 32, according to another example ("Example 33"), the aqueous humor diffusing member further includes a fourth proliferative diffusion membrane configured to allow tissue ingrowth, the fourth proliferative diffusion membrane being positioned adjacent to the second proliferative diffusion membrane and extending along the fluid conduit.

[0036] According to another example ("Example 34") in addition to any of Examples 31-33, the method further includes perforating one of the first, second, third, or fourth proliferative diffusion membranes to include a plurality of pores sized to permit tissue ingrowth.

[0037] In addition to any of Examples 32 to 34, according to another example ("Example 35"), the third proliferative diffusion membrane and the first proliferative diffusion membrane are the same proliferative diffusion membrane.

[0038] In addition to any of Examples 33 to 35, according to another example ("Example 36"), the fourth proliferative diffusion membrane and the second proliferative diffusion membrane are the same proliferative diffusion membrane.

[0039] According to another example ("Example 37") in addition to any of Examples 33-36, the fourth proliferative diffusion membrane includes perforations sized to accommodate a fluid conduit such that, upon implantation, the fluid conduit can extend through the perforations into the anterior chamber.

[0040] According to another example ("Example 38"), a biological fluid drainage device includes a body including a first microporous membrane, a second microporous membrane, and a third microporous membrane, the first microporous membrane disposed between the second and third microporous membranes, the first microporous membrane including a plurality of pores sized to resist tissue ingrowth, and the second and third microporous membranes each including a plurality of pores sized to permit tissue ingrowth, an expandable reservoir defined between the first and third microporous membranes, and the fluid conduit has a first end and a second end, the first end fluidly coupled to the reservoir and the second end extending exterior to the body, and is insertable into a fluid-filled body cavity such that fluid from the fluid-filled body cavity can be transferred to the reservoir.

[0041] In addition to any of the above examples, according to another example ("Example 39"), one or more of the first and fourth microporous membranes are hydrophobic and the second and third microporous membranes are hydrophilic. [Brief description of the drawings]

[0042] BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings are included to provide a further understanding of embodiments of the present disclosure, are incorporated in and constitute a part of this specification, illustrate examples, and together with the description, serve to explain the principles of the present disclosure.

[0043] [Figure 1] FIG. 1 is a diagram of a glaucoma drainage system consistent with various embodiments of the present disclosure.

[0044] [Figure 2A] FIG. 2A is a diagram of a glaucoma drainage system in a contracted state consistent with various embodiments of the present disclosure.

[0045] [Figure 2B] FIG. 2B is a diagram of a glaucoma drainage system in an inflated state consistent with various embodiments of the present disclosure.

[0046] [Diagram 3] FIG. 3 is an exploded view of the glaucoma drainage system shown in FIG.

[0047] [Figure 4] 4A-4D are diagrams of constricting diffusion membrane interface surfaces consistent with various embodiments of the present disclosure.

[0048] [Diagram 5] FIG. 5 is a diagram of a glaucoma drainage system consistent with various embodiments of the present disclosure.

[0049] [Figure 6] FIG. 6 is a diagram of a glaucoma drainage system consistent with various embodiments of the present disclosure.

[0050] [Figure 7A] FIG. 7A is a diagram of a glaucoma drainage system in a contracted state consistent with various embodiments of the present disclosure.

[0051] [Figure 7B] FIG. 7B is a diagram of a glaucoma drainage system in an inflated state consistent with various embodiments of the present disclosure.

[0052] [Figure 8] FIG. 8 is a diagram of a fluid conduit consistent with various embodiments of the present disclosure.

[0053] [Figure 9A] FIG. 9A is a diagram of a glaucoma drainage system consistent with various embodiments of the present disclosure.

[0054] [Figure 9B] FIG. 9B is a cross-sectional view of the glaucoma drainage system of FIG. 9A taken along line 9B-9B.

[0055] [Figure 9C] FIG. 9C is a cross-sectional view of the glaucoma drainage system of FIG. 9A taken along line 9C-9C.

[0056] [Figure 10] FIG. 11 is an exploded view of a glaucoma drainage system consistent with various aspects of the present disclosure.

[0057] [Figure 11] FIG. 11 is a diagram of a glaucoma drainage system implanted within ocular tissue consistent with various embodiments of the present disclosure.

[0058] [Figure 12] FIG. 12 is an illustration of a glaucoma drainage system implanted within ocular tissue consistent with various aspects of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0059] Detailed Description Those skilled in the art will readily understand that the various embodiments of the inventive concepts provided in this disclosure can be realized by any number of methods and devices configured to perform the intended functions. It should also be noted that the accompanying drawings referred to herein are not necessarily drawn to scale and may be exaggerated to illustrate various aspects of the present disclosure, and in that respect, the drawings should not be construed as limiting. As used herein, the term "diffusion membrane" is intended to include one or more proliferative diffusion membranes and / or one or more constrictive diffusion membranes.

[0060] Various aspects of the present disclosure are directed to glaucoma drainage devices, systems and methods. More specifically, the present disclosure relates to devices, systems and methods for draining aqueous humor from the anterior chamber of a patient's eye so that it can be reabsorbed by the body. Providing a mechanism for reabsorption of drained aqueous humor from the anterior chamber of the eye operates to reduce or otherwise stabilize intraocular pressure.

[0061] A glaucoma drainage system 1000 according to some embodiments is shown in FIG. The glaucoma drainage system 1000 is an implantable medical system that operates to facilitate drainage of fluids, such as aqueous humor, from a fluid-filled body cavity, such as the anterior chamber of the eye. The glaucoma drainage system 1000 includes a body, such as a fluid conduit 1500 and an aqueous humor diffusing member 1002. Although the following disclosure refers to the glaucoma drainage system 1000 for use in draining aqueous humor from the anterior chamber of the eye, it should be understood and appreciated by those skilled in the art that the depicted glaucoma drainage system 1000 can be configured and utilized to drain other fluids from other fluid-filled body cavities. In some instances, as described in more detail below, the glaucoma drainage system 1000 further serves to facilitate reabsorption of the drained fluid by the body. For example, in some embodiments, the glaucoma drainage system 1000 provides an interface between the drained aqueous humor and tissues, ducts, and / or cells that have the ability to absorb the aqueous humor and are in sufficient proximity to the glaucoma drainage system 1000 to interact with the drained aqueous humor. Thus, in some instances, aqueous humor drained from the anterior chamber of the eye passes through the glaucoma drainage system 1000 before being reabsorbed by the body.

[0062] In some embodiments, when the glaucoma drainage system 1000 is implanted, aqueous humor drains from the anterior chamber through the fluid conduit 1500. The drained aqueous humor then enters a reservoir in the aqueous humor diffusing member 1002 and permeates through one or more porous membranes of the aqueous humor diffusing member 1002, where it may then be reabsorbed by the body. In various embodiments, in addition to aqueous humor permeability, tissue ingrowth is permitted or promoted along one or more regions of the glaucoma drainage system 1000. For example, the exterior of the aqueous humor diffusing member 1002 can include or be defined by one or more membranes that are porous or otherwise permeable to the fluid of the fluid-filled body cavity (hereinafter referred to as diffusion membranes) and are configured to permit or promote tissue ingrowth. Allowing tissue ingrowth along or within the surface of the glaucoma drainage system 1000 helps to promote biointegration of the glaucoma drainage system 1000 into the surrounding tissue (e.g., ocular tissue) and promotes reabsorption of the drained aqueous humor by the surrounding tissue. Additionally, biointegration, including tissue ingrowth and attachment, helps to minimize relative movement between the glaucoma drainage system 1000 and the tissue surrounding said glaucoma drainage system 1000, helping to avoid foreign body tissue response, scarring, and / or ocular tissue irritation that may result in erosion of the glaucoma drainage system 1000 and site infection.

[0063] In various embodiments, the aqueous humor diffusing member 1002 includes an interior region that defines a reservoir of aqueous humor that drains from the anterior chamber through the fluid conduit 1500. The interior region of the aqueous humor diffusing member 1002 can include one or more membranes (hereinafter referred to as diffusion membranes) that are porous or otherwise permeable to the fluid of the fluid-filled body cavity. For example, as discussed in more detail below, the one or more diffusion membranes can be made from a porous medium, such as a polymeric material, that has a microstructure suitable for transporting fluid through the pore spaces of the porous medium. Thus, in some embodiments, the reservoir can be defined by the pore spaces of the one or more diffusion membranes that form the aqueous humor diffusing member 1002. In some embodiments, the aqueous humor diffusing member 1002 can be configured such that a reservoir is additionally or alternatively formed between two or more diffusion membranes that form the aqueous humor diffusing member 1002. For example, in some embodiments, at least a portion of the surface area between adjacently disposed diffusing membranes forming the aqueous humor diffusing member 1002 remains unbonded or unattached such that the adjacently disposed diffusing membranes are operable to separate from one another along at least a portion of their surface areas to form and define reservoirs. In some embodiments, the reservoirs defined between adjacently disposed diffusing membranes are operable to expand or dilate in a controlled manner (to a predetermined profile upon expansion) such that the glaucoma drainage system 1000 does not interfere with normal ocular function (e.g., normal eye movements including rotation and blinking), as discussed further below.

[0064] In various embodiments, the aqueous humor diffusing member 1002 is sized and shaped to be implantable within a patient's anatomy. For example, in some embodiments, the aqueous humor diffusing member 1002 is sized and shaped to be implantable within an incised subconjunctival space (e.g., between the sclera and conjunctiva of a patient's eye). In some embodiments, the aqueous humor diffusing member 1002 is a thin, puck-shaped member. In some embodiments, the aqueous humor diffusing member 1002 has a thickness (e.g., the distance measured between the first outer surface 1004 and the second outer surface 1006) of 0.5 mm or less, e.g., between 0.1 mm and 0.5 mm. However, given different anatomical structures of the human body, the aqueous humor diffusion member 1002 may be thicker than 0.5 mm, provided that the thickness does not interfere with normal functions of the eye (e.g., turning and blinking) or substantially reduce the flexibility of the aqueous humor diffusion member 1002 to such an extent that undesirable relative motion occurs between the glaucoma drainage system 1000 and the surrounding tissue upon implantation, resulting in tissue irritation, foreign body tissue response and / or excessive scarring.

[0065] In some embodiments, the aqueous humor diffusing member 1002 can have a diameter in the range of 5 mm to 15 mm, e.g., 10 mm. In some embodiments, the aqueous humor diffusing member 1002 can be ovoid and can include a major dimension (e.g., along the major axis of the ellipse) of about 30 mm or less and a corresponding minor axis dimension (e.g., along the major axis of the ellipse) of about 10 mm or less. As discussed above, given different anatomical structures of the human body, the aqueous humor diffusing member 1002 can exceed such dimensions (e.g., 15 mm, 10 mm, and 30 mm), provided that such sizes do not substantially interfere with normal ocular function (e.g., turning and blinking) or substantially reduce the flexibility of the aqueous humor diffusing member to such an extent that undesirable relative motion occurs between the glaucoma drainage system 1000 and the surrounding tissue upon implantation, resulting in tissue irritation, foreign body tissue response, and / or excessive scarring. Similarly, the aqueous humor diffusion member 1002 can be less than 5 mm, less than 3 mm, or even less than 3 mm in diameter, provided that the aqueous humor diffusion member 1002 is operable to contain a sufficient amount of the drained aqueous humor and to promote reabsorption of the aqueous humor to constitute an effective treatment for the patient.

[0066] In various embodiments, the fluid conduit 1500 operates to fluidly couple the reservoir to a fluid-filled body cavity (e.g., the anterior chamber of the eye) when implanted in the body, thereby providing a pressure differential between the reservoir and an external environment (e.g., atmosphere) to the glaucoma drainage system 1000. It should therefore be understood that, upon implantation, the pressure in the reservoir is based, at least in part, on the pressure in the fluid-filled body cavity (e.g., the intraocular pressure in the anterior chamber of the eye). In some embodiments, such a pressure differential causes the reservoir to expand or dilate. Further, in some embodiments, such a pressure differential causes the aqueous humor to permeate through the diffusion membrane of the aqueous humor diffusion member 1002. That is, in some embodiments, the drained aqueous humor enters the reservoir and permeates through the diffusion membrane of the aqueous humor diffusion member 1002, and the aqueous humor can then be reabsorbed by the body.

[0067] 2A and 2B, a glaucoma drainage system 1000 is shown that includes an aqueous humor diffusing member 1002 that includes a plurality of diffusing membranes. The aqueous humor diffusing member 1002 includes a first outer surface 1004, a second outer surface 1006 opposite the first outer surface 1004, and a periphery 1008. Figure 2A shows the glaucoma drainage system 1000 in a contracted state. Figure 2B shows the glaucoma drainage system 1000 in an inflated state, with aqueous humor present in an inflatable or expandable reservoir 1010. Although the glaucoma drainage system 1000 is shown in FIG. 2B in an expanded state in which the glaucoma drainage system 1000 is not uniformly expanded (e.g., the first proliferative and constrictive diffusion membranes 1100 and 1200 are shown to have a generally non-linear configuration, while the second proliferative and constrictive diffusion membranes 1300 and 1400 are shown to have a generally linear configuration), it should be understood that the glaucoma drainage system 1000 may deform uniformly (e.g., the second proliferative and constrictive diffusion membranes 1300 and 1400 may deform in a manner that mirrors the deformation of the first proliferative and constrictive diffusion membranes 1100 and 1200). The aqueous humor diffusing member 1002 includes a body defined by a plurality of diffusion membranes, including first and second proliferative diffusion membranes 1100 and 1400 and first and second constrictive diffusion membranes 1200 and 1300. In some embodiments, the first and second proliferative diffusion membranes 1100 and 1400 and the first and second constrictive diffusion membranes 1200 and 1300 are stacked together as shown to form the aqueous humor diffusing member 1002. As described further below, the first and second proliferative diffusion membranes 1100 and 1400 are configured to permit tissue ingrowth and attachment, and the first and second constrictive diffusion membranes 1200 and 1300 are configured to minimize, resist, or prevent tissue ingrowth and attachment.

[0068] In some embodiments, the first and second proliferative diffusion membranes 1100 and 1400 form or otherwise define the exterior of the aqueous humor diffusion member 1002, while the first and second constrictive diffusion membranes 1200 and 1300 are located between the first and second proliferative diffusion membranes 1100 and 1400 and define the interior region of the aqueous humor diffusion member 1002. In various embodiments, the first and second proliferative diffusion membranes 1100 and 1400 and the first and second constrictive diffusion membranes 1200 and 1300 are each permeable to aqueous humor, respectively, in that each is configured to allow drained aqueous humor (e.g., aqueous humor disposed in a sealed reservoir) to permeate therethrough and / or diffuse across it. However, the first and second proliferative diffusion membranes 1100 and 1400 are configured to allow tissue ingrowth and attachment, while the first and second constrictive diffusion membranes 1200 and 1300 are configured to minimize, resist, or prevent tissue ingrowth and attachment. The configuration of the constrictive diffusion membrane sandwiched or otherwise disposed between the proliferative diffusion membranes as shown in Figures 2A and 2B serves to minimize, for example, the entry of bacteria that exceeds the size of the perforations or small holes present in the constrictive diffusion membrane and / or its migration into the anterior chamber of the eye.

[0069] In various examples, the first and second proliferative diffusion membranes 1100 and 1400 of the aqueous humor diffusing member 1002 are microporous, permeable to aqueous humor, and configured to permit ingrowth and / or attachment of ducts and tissue structures. In various embodiments, the first and second constrictive diffusion membranes 1200 and 1300 are also microporous and permeable to aqueous humor, but configured to resist or otherwise minimize ingrowth and attachment of ducts and tissue structures. Thus, in various embodiments, the aqueous humor diffusing member 1002 is made from multiple separate diffusion membranes, including at least the first proliferative diffusion membrane 1100 and at least the first constrictive diffusion membrane 1200.

[0070] 2A and 2B includes separate and distinct first and second proliferative diffusion membranes 1100 and 1400, it should be understood that the aqueous humor diffusing member 1002 can include the first proliferative diffusion membrane 1100 without the need for a separate and distinct second proliferative diffusion membrane 1400. For example, the first proliferative diffusion membrane 1100 can be folded such that the first proliferative diffusion membrane 1100 surrounds the constrictive diffusion membrane portion of the aqueous humor diffusing member 1002 (e.g., the first and / or second constrictive diffusion membranes 1200 and 1300). In some such embodiments, one or more portions of the folded portion of the proliferative diffusion membrane 1100 are joined or welded to adjacent portions of the unfolded portion of the proliferative diffusion membrane 1200 and / or one or more portions of the constrictive diffusion membrane portion of the aqueous humor diffusing member 1002. 2A and 2B includes separate and distinct first and second constrictive diffusion membranes 1200 and 1300, it should be understood that the aqueous humor diffusing member 1002 can include the first constrictive diffusion membrane 1200 without the need for a separate and distinct second constrictive diffusion membrane 1300. For example, the first constrictive diffusion membrane 1200 can be folded upon itself to form a multi-layered constrictive diffusion membrane, with one or more portions of the folded portion of the constrictive diffusion membrane 1200 being joined or welded to an adjacent portion of an unfolded portion of the constrictive diffusion membrane 1200. Additionally, the proliferative diffusion membrane 1100 may be further folded around the folded constricting diffusion membrane 1200, which is folded onto itself with a fluid conduit 1500 located between the folded and unfolded portions of the constricting diffusion membrane 1200. In some such embodiments, a reservoir may be defined between at least the folded and unfolded portions of the constricting diffusion membrane 1200.

[0071] 3 is an exploded view of the glaucoma drainage system 1000 shown in FIGS. 2A and 2B. As shown in FIG. 3, the aqueous humor diffusion member 1002 includes a body defined by a first proliferative diffusion membrane 1100, a first constrictive diffusion membrane 1200, a second constrictive diffusion membrane 1300, and a second proliferative diffusion membrane 1400. As shown, the various proliferative diffusion membranes and constrictive diffusion membranes each include an interface surface and a periphery. For example, the first proliferative diffusion membrane 1100 includes a first interface surface 1102, a second interface surface 1104, and a periphery 1106. In some instances, the first interface surface 1102 of the first proliferative diffusion membrane 1100 corresponds to or otherwise defines the outer surface 1004 of the glaucoma drainage system 1000. 3, the first constricting diffusion membrane 1200 includes a first interface surface 1202, a second interface surface 1204, and a periphery 1206. Similarly, as shown in FIG. 3, the second constricting diffusion membrane 1300 includes a first interface surface 1302, a second interface surface 1304, and a periphery 1306. As shown, the second proliferative diffusion membrane 1400 includes a first interface surface 1402, a second interface surface 1404, and a periphery 1406. In some instances, the second interface surface 1404 of the second proliferative diffusion membrane 1400 corresponds to or otherwise defines the second outer surface 1006 of the glaucoma drainage system 1000.

[0072] In various embodiments, the diffusion films (i.e., the proliferative diffusion film and the constrictive diffusion film) that form the aqueous humor diffusion member 1002 are disposed adjacent to one another in a stacked configuration. For example, as shown in Figures 2A, 2B, and 3, the first and second proliferative diffusion films 1100 and 1400 and the first and second constrictive diffusion films 1200 and 1300 are disposed adjacent to one another in a stacked configuration, with the first and second proliferative diffusion films 1100 and 1400 forming or otherwise defining the exterior of the aqueous humor diffusion member 1002, and the first and second constrictive diffusion films 1200 and 1300 being sandwiched or otherwise disposed between the first and second proliferative diffusion films 1100 and 1400. In this manner, the proliferative diffusion membrane forming the exterior region of the aqueous humor diffusion member 1002 is configured to support or allow tissue in-growth and attachment, while the constrictive diffusion membrane forming the interior region of the aqueous humor diffusion member 1002 is configured to minimize, resist or prevent tissue in-growth and attachment across or into the boundary or interface between the proliferative diffusion membrane and the constrictive diffusion membrane.

[0073] By minimizing, resisting or preventing tissue ingrowth and adhesion across or into the constricting diffusion membrane, the glaucoma drainage system 1000 minimizes, resists or prevents tissue ingrowth into the reservoir 1010, which helps maintain the performance of the glaucoma drainage system during and after biointegration. For example, by minimizing, resisting or preventing tissue ingrowth into the constricting diffusion membrane, the reservoir 1010 thus operates to maintain the flexibility of the glaucoma drainage system 1000, which helps to minimize relative movement between the glaucoma drainage system 1000 and the surrounding tissue, as discussed herein, and thus helps to minimize irritation of the surrounding tissue. In particular, minimizing, resisting or preventing tissue ingrowth into the stenotic diffusive membranes helps to avoid tissue proliferation beyond the interface between adjacent stenotic diffusive membranes, and thus helps to avoid such tissue ingrowth interlocking the stenotic diffusive membranes. Preventing interlocking of the stenotic diffusive membranes helps to maintain the ability of the stenotic diffusive membranes to slide and move relative to one another, which helps to maintain the flexibility of the glaucoma drainage system 1000.

[0074] In some instances, as discussed further below, the aqueous humor diffusing membrane 1002 is configured such that the interface surfaces of adjacently disposed diffusion membranes face each other. In some instances, the first and second proliferative diffusion membranes 1100 and 1400 and the first and second constrictive diffusion membranes 1200 and 1300 are oriented such that their peripheries are aligned and / or coaxial with each other. In some embodiments, one or more peripheries of the diffusion members forming the body of the aqueous humor diffusing member 1002 form the periphery 1008 of the aqueous humor diffusing member 1002. For example, as shown in Figures 2A and 2B, the peripheries 1106, 1206, 1306, and 1406 collectively form or define the periphery 1008 of the aqueous humor diffusing member 1002. However, it should be understood that the periphery of the aqueous humor diffusing member 1002 may be formed from less than all of the peripheries of the diffusion membranes forming the body of the aqueous humor diffusing member 1002. For example, in some instances, the periphery 1008 of the aqueous humor diffusing member 1002 can be formed or defined by the peripheries 1106 and 1406 of the first and second proliferative diffusing membranes 1100 and 1400 .

[0075] As described above, in various embodiments, adjacently disposed diffusion membranes are generally oriented such that one or more of their interface surfaces are disposed adjacent to or otherwise facing the interface surface of the adjacently disposed diffusion membrane. That is, in various embodiments, the interface surfaces of adjacently disposed diffusion membranes face each other. In the embodiment shown in Figures 2A, 2B, and 3, the first proliferative diffusion membrane 1100 and the first constricting diffusion membrane 1200 are disposed adjacent to each other such that the second interface surface 1104 of the first proliferative diffusion membrane 1100 faces the first interface surface 1202 of the first constricting diffusion membrane 1200. Similarly, as shown in Figures 2A, 2B, and 3, the first constricting diffusion membrane 1200 and the second constricting diffusion membrane 1300 are disposed adjacent to each other such that the second interface surface 1204 of the first constricting diffusion membrane 1200 faces the first interface surface 1302 of the second constricting diffusion membrane 1300. Similarly, as shown in Figures 2A, 2B and 3, the second constricting diffusion membrane 1300 and the second proliferative diffusion membrane 1400 are positioned adjacent to each other such that the second interface surface 1304 of the second constricting diffusion membrane 1300 faces the first interface surface 1402 of the second proliferative diffusion membrane 1400.

[0076] Thus, in some embodiments, a stack configuration as described above provides a first diffusion film having first and second interface surfaces and a second diffusion film having first and second interface surfaces, where the first and second diffusion films are adjacently positioned such that the second interface surface of the first diffusion film faces the first interface surface of the second diffusion film.

[0077] In various embodiments, the first and second proliferative diffusion membranes 1100 and 1400 and the first and second constrictive diffusion membranes 1200 and 1300 can include or be formed from one or more layers or sheets of expanded polytetrafluoroethylene (ePTFE) or other polymers, such as, but not limited to, polyurethane, polysulfone, polyvinylidene fluoride or polyvinylidene fluorine (PVDF), polyhexafluoropropylene (PHFP), perfluoroalkoxy polymers (PFA), polyolefins, fluorinated ethylene propylene (FEP), acrylic copolymers, and other suitable fluorocopolymers. These polymers can be in the form of sheets, knits, or wovens (including individual or multi-fiber strands) or nonwovens in porous form. In some instances, one or more of the first and second proliferative diffusion membranes 1100 and 1400 and / or the first and second constrictive diffusion membranes 1200 and 1300 may be formed from multiple layers or sheets of polymeric material. In some such instances, the layers or sheets of polymeric material may be laminated or otherwise mechanically bonded together, such as by heat treatment and / or high pressure compression and / or adhesives and / or other lamination methods known to those skilled in the art. In some embodiments, as described in more detail below, layers of polymeric material may be bonded together at distinct locations to form stabilizing structures extending through the resulting proliferative and / or constrictive diffusion membranes. Similarly, in some embodiments, as described in more detail below, proliferative and / or constrictive diffusion membranes may be bonded together at distinct locations to form stabilizing structures extending through the resulting aqueous humor diffusion member 1002. As discussed above, it should be appreciated that such stabilizing structures are operable to constrain the shape or profile of the aqueous humor diffusing member 1002 upon expansion or inflation of the reservoir 1010.

[0078] In some embodiments, the layers or sheets of polymeric material forming the first and / or second proliferative diffusion membranes 1100 and 1400 and / or the first and / or second constrictive diffusion membranes 1200 and 1300 can be subjected to one or more processes before or after processing to modify their microstructure (and thus their material properties) to increase or decrease the natural permeability (e.g., aqueous humor permeability) of the polymeric material. In some examples, such processes include, but are not limited to, material coating processes, surface preconditioning processes, and / or perforation processes. As will be appreciated by those skilled in the art, material coating processes can be utilized to at least partially fill the porous spaces of the polymeric material, thereby reducing permeability. Additionally or alternatively, material coating processes can be used to apply one or more drugs or antimicrobial coatings (e.g., metal salts such as silver carbonate) to the surface of the polymeric material and organic compounds (e.g., chlorhexidine diacetate) to the polymeric material.

[0079] In some embodiments, one or both of the first and second proliferative diffusion membranes 1100 and 1400 and / or one or both of the first and second constrictive diffusion membranes 1200 and 1300 can be hydrophilic. In some embodiments, one or both of the first and second proliferative diffusion membranes 1100 and 1400 and / or one or both of the first and second constrictive diffusion membranes 1200 and 1300 are hydrophobic. Thus, in some instances, the aqueous humor diffusing member 1002 can include one or more hydrophilic membranes and one or more hydrophobic membranes.

[0080] Thus, hydrophilic coatings that allow wetting of the polymer matrix may be applied when the polymer surface is hydrophobic in nature. Surface coatings containing antioxidant components may be applied to mitigate the body's inflammatory response that occurs naturally during post-operative wound healing. Surfaces can be modified with anti-proliferative compounds (e.g., mitomycin C, 5-fluoracil) to mitigate the response of surrounding tissues in the eye. In some instances, one or more surface preconditioning processes can additionally or alternatively be utilized to form layers that exhibit favorable microstructures (e.g., wrinkles, folds, or other geometric out-of-plane structures), as described in U.S. Pat. No. 9,849,629 to Zagl et al. Such surface preconditioning can promote a more aggressive initial inflammatory phase post-operatively and provide an early stable interface between the porous device and tissue. In some instances, heparin coatings (e.g., thrombogenic) can additionally or alternatively be applied to help minimize or reduce cell formation, including fibrinogen accumulation, following surgical implantation procedures.

[0081] In some embodiments, in addition to the naturally occurring perforations or pores in the polymeric material, one or more perforation processes can additionally or alternatively be utilized to form multiple perforations or pores in the polymeric material, which operates to increase the natural permeability (e.g., permeability to aqueous humor) of the polymeric material. Such perforation processes can increase the number of perforations or pores present in the polymeric material and / or can increase the average size of the perforations or pores present in the polymeric material, and can be performed before and / or after the formation of the proliferative and / or constrictive diffusion membranes. In some embodiments, the permeability of the first and / or second proliferative diffusion membranes 1100 and 1400 and / or the first and second constrictive diffusion membranes 1200 and 1300 can be altered to adjust or otherwise change the flux and / or flow resistance of aqueous humor to a desired amount.

[0082] In various embodiments, the first and / or second proliferative diffusion membranes 1100 and 1400 can include perforations or pores ranging in size (or average size) from 20 microns to 100 microns. In other examples, the size (or average size) of the perforations or pores of the first and / or second proliferative diffusion membranes 1100 and 1400 can be greater than 150 microns. In various embodiments, the first and / or second proliferative diffusion membranes 1100 and 1400 can include perforations or pores that are less than 20 microns but greater than 1 or 2 microns, since perforations or pores smaller than 1 or 2 microns generally inhibit, resist or otherwise prevent ingrowth of ducts and other tissues.

[0083] Thus, in various embodiments, the first and second constrictive diffusion membranes 1200 and 1300 are configured or selected such that the size (average size) of the perforations or pores therein is generally less than 1 or 2 microns, minimizing, resisting or preventing tissue ingrowth and attachment while maintaining aqueous humor permeability.

[0084] It should be understood that the first and second proliferative diffusion membranes 1100 and 1400 can be configured to have the same or different permeabilities. Similarly, it should be understood that the first and second constrictive diffusion membranes 1200 and 1300 can be configured to have the same or different permeabilities. In some instances, the various proliferative and constrictive diffusion membranes discussed herein can have the same inherent permeability, but can undergo one or more of the material modification processes discussed herein to achieve different relative permeabilities. In some embodiments, one or more of the material modification processes discussed herein operate to modify or otherwise change the naturally occurring permeability of the polymeric material. Thus, in some embodiments, the permeability of the proliferative and / or constrictive diffusion membranes can be based on the naturally occurring microstructure of the polymeric material and / or one or more of the material modification processes discussed herein. Those skilled in the art will understand that permeability generally relates to the resistance of a fluid to transport through the pore space of a porous medium, with materials associated with low permeability exhibiting greater flow resistance than materials having higher permeability.

[0085] In some embodiments, the perforations or pores in the proliferative and constrictive diffusion membranes may be formed by one or more salt inclusion processes, or by using one or more of drilling, die punching, needle punching, or laser cutting processes, which may occur before and / or after the formation of the proliferative and / or constrictive diffusion membranes.

[0086] In general, the above processes can be used to form a proliferative diffusion membrane having a microstructure that allows the ingrowth of surrounding ducts and other tissues and is permeable to aqueous humor. Similarly, the above processes can be used to form a constrictive diffusion membrane having a microstructure that minimizes, resists or prevents the ingrowth of surrounding ducts and other tissues, but is permeable to aqueous humor. Aqueous humor that permeates and / or diffuses across the constrictive and proliferative diffusion membranes can be absorbed into ducts grown into the proliferative diffusion membrane and / or ducts external to the aqueous humor diffusing member 1002 and / or permeate through the surrounding tissue into the tear film.

[0087] As mentioned above, in some embodiments, the pressure differential observed between the reservoir 1010 of the glaucoma drainage system 1000 and the external environment of the glaucoma drainage system 1000 (e.g., atmospheric pressure) is the mechanism that facilitates the flow of aqueous humor through the aqueous humor diffusing member 1002 of the glaucoma drainage system 1000. In some embodiments, the mechanism of reabsorption and transport of the drained aqueous humor by the conduits that have grown in and around the glaucoma drainage system 1000 facilitates the drainage of aqueous humor from the anterior chamber.

[0088] It should be appreciated, however, that in addition to facilitating reabsorption and transport of the drained aqueous humor, the ingrowth of tissue, ducts and cells into the proliferative diffusion membrane of the aqueous humor diffusing member 1002 also helps to prevent, reduce, minimize or limit the onset of a foreign body tissue reaction. Specifically, as discussed above, the tissue ingrowth and attachment helps to minimize relative movement between the glaucoma drainage system 1000 and the ocular tissue. By helping to minimize such relative movement, the glaucoma drainage system 1000 helps to avoid ocular tissue irritation that may occur and lead to excessive scarring and / or erosion of the glaucoma drainage 1000 and a foreign body tissue reaction that may cause site infection.

[0089] In some embodiments, one or more adjacently disposed diffusing films forming the body of the aqueous humor diffusing member 1002 are joined or otherwise bonded together. In some embodiments, adjacently disposed diffusing films are bonded at one or more distinct portions or areas along their adjacent opposing interfacial surfaces. In some embodiments, adjacently disposed diffusing films may be bonded along at least a portion of an adjacent edge (or edges). In other embodiments, adjacently disposed diffusing films may additionally or alternatively be bonded at one or more distinct locations along adjacent surfaces inside an edge (or edges). In still other embodiments, adjacently disposed diffusing films may be bonded along the entirety of their adjacent opposing interfacial surfaces (e.g., by applying adhesive to the entire surface area of ​​the adjacent opposing interfacial surfaces). Thus, in some embodiments, one or more adjacently disposed diffusing films may be bonded at less than all of their adjacent opposing interfacial surfaces (e.g., at distinct locations or portions thereof) or may be bonded along the entirety of the opposing interfacial surfaces.

[0090] In embodiments in which adjacently disposed diffusion films are bonded along less than all of their adjacently opposed interfacial surfaces, one or more distinct locations along the adjacently opposed interfacial surfaces are joined or otherwise bonded, while one or more other distinct locations along the adjacently opposed interfacial surfaces are not joined or otherwise bonded, i.e., in some embodiments, at least one region or area of ​​the adjacently opposed interfacial surfaces is intentionally left unattached, unjoined, or otherwise unbonded.

[0091] In some such embodiments, these non-bonded regions or areas may include regions or areas that are central to the periphery. In general, these non-bonded regions or areas may be free to move or slide relative to one another and separate relative to one another to act as reservoirs for the accumulation of drained aqueous humor. In various examples, the provision of such degrees of freedom (e.g., in shear) provides significant flexibility, as the diffusing membranes can move relative to one another to accommodate changes in curvature as the aqueous humor diffusing member 1002 flexes and moves, such as during natural eye movements. Thus, the discontinuity of the diffusing membrane bonds provides a glaucoma drainage system 1000 that exhibits better ocular conformity and is better suited to dynamically respond to changes in the curvature of the eye 2000 as the patient blinks, focuses, and moves the eye in the orbit. The increased flexibility also minimizes movement of the glaucoma drainage system 1000 relative to the surrounding tissue, unlike more rigid conventional designs.

[0092] 4A-4D, examples of interface surfaces including bonded and non-bonded (e.g., bonded and non-bonded) regions are shown. FIG. 4A is a cross-sectional view of the second interface surface 1204 taken along a boundary (4-4, FIG. 2) located between adjacent opposing first and second interface surfaces 1204 and 1302, with the fluid conduit 1500 removed for clarity. As mentioned above, in some embodiments, adjacent opposing interface surfaces can be bonded to each other at multiple distinct locations such that the adjacent opposing interface surfaces include bonded and non-bonded regions. FIG. 4A shows the second interface surface 1204 of the first constricting diffusion membrane 1200 including a bonded region 1210 (shown as a cross-hatched region) where the second interface surface 1204 is bonded to the adjacent opposing first interface surface 1302 of the second constricting diffusion membrane 1300 in addition to bonding along the periphery 1206. As shown in Figure 4A, the second interface surface 1204 of the first constricting diffusion membrane 1200 also includes a non-bonded region 1208 (shown as the region between and around the cross-hatched regions) where the second interface surface 1204 is adjacent to, but not bonded to, the adjacent opposing first interface surface 1302 of the second constricting diffusion membrane 1300. In this illustrated example of Figure 4A, the adjacent opposing first and second interface surfaces 1204 and 1302 are free to slide and move relative to one another along the non-bonded region 1208. Furthermore, these non-bonded regions 1208 are free to separate from one another to form reservoirs 1010 for the accumulation of aqueous humor.

[0093] It should be appreciated that the unbonded regions 1208 between the first and second constrictive diffusive membranes 1200 and 1300 shown in Figures 4A-4D are configured to be free to separate from one another to form the reservoir 1010, while the bonded regions 1210 remain bonded. In various examples, these bonded regions 1210 operate to control the profile of the glaucoma drainage system 1000 as the reservoir 1010 expands or dilates.

[0094] Figure 4B is a cross-sectional view of the second interface surface 1204 taken along the boundary (4-4, Figure 2) located between adjacent opposing first and second interface surfaces 1204 and 1302. Figure 4B shows an alternative configuration in which the second interface surface 1204 includes a centrally located bonding region 1210 (shown as a cross-hatched region) and is bonded to an adjacent opposing first interface surface 1302 of a second constricting diffusive membrane 1300 in addition to being bonded along the periphery 1206. Although not shown, it should be understood that the bonding configurations of Figures 4B and 4A may be combined in whole or in part.

[0095] 4C illustrates another configuration in which the second interface surface 1204 includes a peripherally disposed bonding region 1210 (shown as a cross-hatched region) where the second interface surface 1204 is bonded to an adjacent opposing first interface surface 1302 of a second constricting diffusive membrane 1300. Although not shown, it should be understood that the bonding configurations of FIGS. 4C, 4B and / or 4A may be combined in whole or in part.

[0096] FIG. 4D illustrates another alternative configuration in which the second interface surface 1204 includes a peripherally located bonded region 1210 and a concentric annular inner bonded region 1210 (both shown as cross-hatched regions) bonded to an adjacent opposing first interface surface 1302 of a second constrictive diffusion membrane 1300. The configuration illustrated in FIG. 4D includes the possibility of two distinct reservoirs for the accumulation of aqueous humor. The first reservoir corresponds to the radially inner unbonded portion 1208 of the concentric annular inner bonded region 1210 radially inward of the peripherally located bonded region 1210 near the periphery 1206. The second reservoir corresponds to the peripherally located unbonded portion 1208 located between the concentric annular inner bonded region 1210 and the peripherally located bonded region 1210. It should be understood that the first fluid conduit of the configuration illustrated in FIG. 4D is fluidly coupled to the first reservoir, while the second fluid conduit is coupled to the second reservoir. Alternatively, a single fluid conduit may be fluidly coupled to both the first and second reservoirs shown in Figure 4D, such as by corresponding openings in the fluid conduit. In another alternative, less than all of the concentric annular inner coupling region 1210 may be decoupled such that the first and second reservoirs are fluidly coupled. Although not shown, it should be understood that the coupling configurations of Figures 4D, 4C, 4B and / or 4A may be combined in whole or in part.

[0097] 4A-4D depict exemplary bonded and non-bonded (e.g., bonded and non-bonded) regions of the second interfacing surface 1204, it should also be understood that the adjacent opposing first interfacing surface 1302 includes bonded and non-bonded regions that correspond, respectively, to the bonded and non-bonded regions of the second interfacing surface 1204. It should further be understood that the exemplary embodiments of Figures 4A-4D should not be construed as limiting the present disclosure to the illustrated embodiments. Instead, one of ordinary skill in the art will appreciate that virtually any pattern of bonded and non-bonded regions may be utilized without departing from the spirit or scope of the present disclosure.

[0098] The boundary between the first proliferative diffusion film 1100 and the first constricting diffusion film 1200 is not shown, but it should be understood that the adjacent opposing first and second interface surfaces 1202 and 1104 may be uniformly bonded across the boundary or may be bonded according to the embodiments described above. Similarly, the boundary between the second proliferative diffusion film 1400 and the second constricting diffusion film 1300 is not shown, but it should be understood that the adjacent opposing first and second interface surfaces 1402 and 1304 may be uniformly bonded across the boundary or may be bonded according to the embodiments described above.

[0099] As mentioned above, adjacent diffusion films can be connected or bonded to each other by one or more heat treatment processes and / or one or more bonding agents, such as one or more adhesives. In some embodiments, adjacently disposed diffusion films and / or layers of materials forming the diffusion films are partially or fully bonded by thermal methods when each material is above its melting temperature. In some embodiments, such thermal processes promote the formation of adhesive or cohesive bonds between the polymeric materials or layers of polymeric materials. In some embodiments, adjacently disposed diffusion films forming the diffusion films are partially or fully bonded by thermal methods when at least one of the materials is above its melting temperature. In some embodiments, such thermal processes promote the formation of adhesive or cohesive bonds between the materials or layers of materials. In some embodiments, one or more suitable adhesives are utilized to provide a well-bonded interface, which can be continuous or discontinuous.

[0100] As discussed above, in various embodiments, the glaucoma drainage system 1000 is operable or otherwise configured to drain aqueous humor from the anterior chamber (AC) of the eye. In some embodiments, the glaucoma drainage system 1000 includes a fluid conduit 1500, as shown at least in FIG. 1. In various embodiments, the fluid conduit 1500 is a conformable tubular structure (e.g., a catheter) that extends into the aqueous humor diffusing member 1002 and fluidly couples the aqueous humor diffusing member 1002 to the anterior chamber of the eye. The fluid conduit 1500 provides for the outflow of fluid from the anterior chamber. As shown in FIG. 3, the fluid conduit 1500 includes a first end 1502 and a second end 1504, and a lumen extending from the first end 1502 to the second end 1504. In general, the fluid conduit 1500 can be formed from silicone, ePTFE, polycarbonate, polyethylene, polyurethane, polysulfone, PVDF, PHFP, PFA, polyolefins, FEP, acrylic copolymers and other suitable fluorocopolymers, either alone or in combination, or other biocompatible polymers suitable for forming a compliant fluid conduit 1500.

[0101] In some embodiments, the fluid conduit 1500 is formed by a tubular melt extrusion process. In some embodiments, the extruded fluid conduit 1500 can be drawn down to the final target dimensions. In some embodiments, the fluid conduit 1500 is formed via a tube paste extrusion and expansion (stretching) process commensurate with producing the desired wall thickness, porosity, stiffness and / or dimensions. In some embodiments, the fluid conduit 1500 is formed by one or more tape wrapping processes in which a tape is wrapped around a mandrel of a specified dimension and cross-section. In some embodiments, the wrapped tape can be further bonded to itself by one or more heat or adhesive methods before or after removal from the mandrel. In various embodiments, the wrapped tape configuration (e.g., ePTFE) provides a fluid conduit 1500 structure with different layers having different porosities. For example, an inner wrapped layer can be more porous than an outer wrapped layer. In some embodiments, the fluid conduit 1500 is formed by successively dip-coating materials onto an appropriately sized mandrel, followed by removal of the solvent from the formed fluid conduit 1500 and extraction of the mandrel.

[0102] In some embodiments, the diameter of the lumen of the fluid conduit 1500 is sufficient to allow the flow of aqueous humor through the fluid conduit 1500 from the anterior chamber to the aqueous humor diffusion member 1002, but does not result in the fluid conduit 1500 having an outer diameter that significantly inhibits or impairs normal eye function (e.g., does not interfere with blinking or regular eye movements).

[0103] As discussed above, the fluid conduit 1500 fluidly couples the aqueous humor diffusing member 1002 to the anterior chamber of the eye such that aqueous humor can be drained from the anterior chamber and delivered to the aqueous humor diffusing member 1002, and in particular to a reservoir defined within an interior region of the aqueous humor diffusing member 1002. Thus, the fluid conduit 1500 is configured to extend between the anterior chamber of the eye and a location in the eye to which the aqueous humor diffusing member 1002 is attached or otherwise integrated. In some embodiments, the length of the fluid conduit 1500 can be between 1 mm and 30 mm, although typically the length of the fluid conduit 1500 is oversized (or longer than necessary) to allow a physician to trim the length to a particular length required for a patient's unique anatomy. However, in various embodiments, the length and diameter of the lumen of the fluid conduit 1500 are preselected to control the pressure drop across the length to minimize the risk of hypotension (e.g., dangerously low intraocular pressure) since the pressure drop across the fluid conduit 1500 is a function of the length of the fluid conduit 1500. In some embodiments, the fluid conduit 1500 may be pre-marked with a cut-off length identification that corresponds to the theoretically expected pressure drop when implanted. Such a configuration gives the physician the option to tailor the pressure drop to the patient's particular needs. In such an embodiment, after trimming the fluid conduit 1500 to a length that corresponds to the desired pressure drop, the physician optionally advances the first end 1502 of the fluid conduit 1500 further into the anterior chamber or positions the aqueous humor diffusion member 1002 from the penetration point of the fluid conduit 1500 into the anterior chamber (e.g., further around the eye) to receive the desired length.

[0104] In various embodiments, the fluid conduit 1500 may be porous or non-porous, or may include a combination of porous and non-porous portions. For example, in some embodiments, the fluid conduit 1500 may have a length defined by a first portion (or region) and a second portion (or region). In some embodiments, the first portion may be a non-porous portion and the second portion may be a porous portion. In some embodiments, the non-porous portion is impermeable to aqueous humor, while the porous portion is permeable to aqueous humor. Thus, in some embodiments, aqueous humor drained from the anterior chamber by the fluid conduit 1500 may permeate through the porous portion of the fluid conduit 1500. For example, the portion of the fluid conduit 1500 within the anterior chamber may have an outer surface that is impermeable to aqueous humor or cellular infiltration, while the portion of the fluid conduit 1500 outside the anterior chamber may permit or otherwise enable cellular infiltration and tissue ingrowth and biointegration. In some embodiments, the inner surface of the fluid conduit 1500 can be impermeable to aqueous humor and is configured to minimize bacterial ingress and ingrowth of the conduits and tissue structures.

[0105] In some embodiments, the porous portion of the fluid conduit 1500 may be formed by subjecting a region (e.g., a portion of the length of the fluid conduit 1500) to one or more of the perforation processes described above to form a plurality of perforations in the region of interest. However, the fluid conduit 1500 need not include a portion that is permeable to aqueous humor.

[0106] In general, the flow of aqueous humor through the glaucoma drainage system 1000 is governed by the pressure difference between the intraocular pressure and the pressure within the aqueous humor diffusing member 1002 (e.g., a function of forces acting on the aqueous humor diffusing member 1002, such as atmospheric pressure). The pressure difference between these pressure regions causes aqueous humor to flow from the anterior chamber into the glaucoma drainage system 1000. In some embodiments, the rate at which aqueous humor flows through the glaucoma drainage system 1000 is governed by this pressure difference and the resistance to flow. In some embodiments, the resistance to flow is a function of the fluid conduit flux resistance (e.g., based on the geometry, diameter, and length of the tube, typically based on the Hagen-Poiseuille equation) and the resistance to flux of aqueous humor through the aqueous humor diffusing member 1002, as would be understood by one of ordinary skill in the art. In some embodiments, as discussed above, the resistance to flux of aqueous humor through the aqueous humor diffusing member 1002 can be controlled by the permeability of the underlying material forming the aqueous humor diffusing member 1002.

[0107] As discussed above, the fluid conduit 1500 is a soft, malleable, biocompatible tubular structure. In some embodiments, the fluid conduit 1500 is malleable in that it exhibits low column strength and is generally unable to support its own weight. That is, in some embodiments, the fluid conduit 1500 lacks a sufficient amount of structural integrity (e.g., compressive hoop strength) necessary to avoid collapse (e.g., collapse of an inner lumen extending through the fluid conduit 1500) under its own weight.

[0108] In some embodiments, intraocular pressure in the anterior chamber expands or otherwise acts to maintain the generally tubular geometry of the fluid conduit 1500 (e.g., avoiding collapse of the lumen 1506A). That is, in some embodiments, aqueous humor flowing through the lumen of the fluid conduit 1500 operates to expand the lumen. Such a configuration provides a soft, flexible fluid conduit 1500 that conforms to the curvature of the eye and avoids interfering with normal eye functions (e.g., rotation and blinking). It should be understood that in some embodiments, the fluid conduit 1500 may instead be constructed to exhibit a sufficient amount of structural integrity to maintain its generally tubular geometry and / or avoid collapse of the lumen.

[0109] 3, in some embodiments, the fluid conduit 1500 includes a first end 1502 and an opposing second end 1504. In some embodiments (not shown in FIG. 3), the fluid conduit 1500 includes a lumen extending from the first end 1502 to the second end. In some embodiments, the first end 1502 is insertable into the anterior chamber and the second end 1504 is inserted into or otherwise attached to the aqueous humor diffusing member 1002. In some embodiments, the first end 1502 is positionable within the anterior chamber such that the first end 1502 extends into an interior region of the anterior chamber.

[0110] In some embodiments, after the first end 1502 of the fluid conduit 1500 is placed in the anterior chamber, the fluid conduit 1500 can be secured to prevent dislodgment of the fluid conduit 1500 from within the anterior chamber. In some embodiments, one or more sutures are utilized to join the fluid conduit 1500 and / or the aqueous humor diffusion member 1002 to the ocular tissue. In some embodiments, a biocompatible tissue adhesive is used to bond the fluid conduit 1500 and / or the aqueous humor diffusion member 1002 to the surrounding or adjacent tissue. In some embodiments, a needle track made through tissue prior to placement of the fluid conduit 1500 can be sized to provide sufficient interface fit with the fluid conduit 1500 over the length of the needle track. In some embodiments, the first end 1502 of the fluid conduit 1500 may additionally or alternatively be flared to a larger diameter than other portions (e.g., a central portion) of the fluid conduit 1500 (or a lumen within tissue through which the fluid conduit 1500 extends) to create an interference attachment that helps maintain placement of the first end 1502 within the anterior chamber of the eye. In some instances, the flared first end 1502 of the fluid conduit 1500 helps to prevent the fluid conduit 1500 from becoming dislodged from its position within the anterior chamber.

[0111] In some embodiments, the second end 1504 of the fluid conduit 1500 is coupled to the aqueous humor diffusing member 1002 such that a reservoir defined within the aqueous humor diffusing member 1002 is fluidly coupled with the fluid conduit 1500 and thus with a fluid-filled body cavity (e.g., the anterior chamber of the eye) when the glaucoma drainage system 1000 is implanted within the body. In some embodiments, the second end 1504 of the fluid conduit 1500 extends or otherwise terminates within the aqueous humor diffusing member 1002, such as between the first and second constricting diffusion membranes 1200 and 1300 that define the reservoir. For example, as shown in FIG. 5, the fluid conduit 1500 is coupled to the aqueous humor diffusing member 1002 such that the fluid conduit 1500 terminates within the aqueous humor diffusing member 1002. That is, in some embodiments, the second end 1504 is coupled to the aqueous humor diffusing member 1002 such that drained aqueous humor exiting the fluid conduit 1500 at the second end 1504 diffuses or otherwise is injected into the aqueous humor diffusing member 1002 beginning at a location interior to the periphery 1008. Although not shown separated from one another in FIG. 5, it should be understood that the first and second constricting diffusion membranes 1200 and 1300 are operable to be separated from one another such that the reservoirs are expandable or expandable, as described above.

[0112] 5, aqueous humor traveling through the fluid conduit 1500 along arrow 1602 exits the second end 1504 of the fluid conduit 1500 and diffuses or otherwise infuses into the reservoir 1010. As discussed above, the reservoir 1010 may include the pore space of the first and second constricting diffusion membranes 1200 and 1300 and / or the area defined between the first constricting diffusion membrane 1200 and the second constricting diffusion membrane 1300. As shown in FIG. 5, aqueous humor is shown exiting the fluid conduit 1500 and into the reservoir 1010, which includes at least the area defined between the first and second constricting diffusion membranes 1200 and 1300.

[0113] As the discharged aqueous humor permeates through the constricting diffusion membrane of the aqueous humor diffusing member 1002, the aqueous humor generally seeps outwardly of the aqueous humor diffusing member 1002, as indicated by arrows 1604A-1604E. It should be understood that arrows 1604A-1604E are not intended to represent the actual path of the aqueous humor, but rather to represent the aqueous humor permeating away from an interior region, such as the reservoir 1010, of the aqueous humor diffusing member 1002, or at least away from the second end 1504 of the fluid conduit 1500.

[0114] In some other embodiments, the second end 1504 of the fluid conduit 1500 is coupled to the periphery 1008 of the aqueous humor diffusing member 1002. For example, as shown in FIG. 6, the second end 1504 of the fluid conduit 1500 is coupled to the aqueous humor diffusing member 1002 at its periphery 1008. That is, in some embodiments, the second end 1504 is coupled to the aqueous humor diffusing member 1002 such that draining aqueous humor exiting the fluid conduit 1500 at the second end 1504 diffuses or otherwise is injected into the first and second constricting diffusion membranes 1200 and 1300 that originate at or near the periphery 1008 of the aqueous humor diffusing member 1002.

[0115] In some such embodiments, as the drained aqueous humor permeates through the aqueous humor diffusing member 1002, the aqueous humor can permeate toward the interior of the aqueous humor diffusing member 1002 and / or can permeate toward the exterior of the aqueous humor diffusing member 1002. In some embodiments, as described above, the aqueous humor traveling through the fluid conduit 1500 exits at the second end 1504 of the fluid conduit 1500 between the first and second constrictive diffusion membranes 1200 and 1300. Also as described above, the aqueous humor enters the reservoir 1010 of the aqueous humor diffusing member 1002, which can be defined between the first and second constrictive diffusion membranes 1200 and 1300, or can additionally or alternatively correspond to the pore space of the first constrictive diffusion membranes 1200 and 1300. As described above, the glaucoma drainage system 1000 is configured to allow the drained aqueous humor to permeate from the interior of the aqueous humor diffusing member 1002 toward the exterior of the aqueous humor diffusing member 1002.

[0116] Arrows 1604A-1604C in FIG. 6 represent aqueous humor generally permeating the aqueous humor diffusing member 1002. As shown, arrow 1604A represents aqueous humor permeating the aqueous humor diffusing member 1002 generally toward an interior region of the aqueous humor diffusing member 1002, while arrows 1604B and 1604C represent aqueous humor permeating through the aqueous humor diffusing member 1002 generally toward an exterior region of the aqueous humor diffusing member 1002. As discussed above, it should be understood that arrows 1604A-1604C are not intended to represent the actual path of aqueous humor, but instead are intended to represent aqueous humor permeating at least away from the second end 1504 of the fluid conduit 1500. Although not shown separated from one another in FIG. 6, it will be understood that the first and second constricting diffusion membranes 1200 and 1300 are operable to separate from one another to define a reservoir 1010 therebetween.

[0117] In various embodiments, the second end 1504 of the fluid conduit 1500 may be coupled to the periphery 1008 of the aqueous humor diffusion member 1002 by adhesive, welding, suturing, or one or more mechanical fasteners. In some embodiments, the second end 1504 of the fluid conduit 1500 may be coupled to the periphery 1008 by one or more thermal bonding methods described above to create an adhesive or cohesive bond between materials or layers of materials.

[0118] In various embodiments, the fluid conduit 1500 is coupled to the aqueous humor diffusing member 1002 such that the drained aqueous humor exiting the fluid conduit 1500 at the second end 1504 diffuses through the constricting diffusion membrane before diffusing through the proliferative diffusion membrane. For example, as shown in Figures 5 and 6, the second end 1504 of the fluid conduit 1500 is coupled to the aqueous humor diffusing member 1002 such that the drained aqueous humor exiting the fluid conduit 1500 at the second end 1504 diffuses through one or more of the first and second constricting diffusion membranes 1200 and 1300 before diffusing through the first and second proliferative diffusion membranes 1100 and 1400.

[0119] Unlike conventional designs, the glaucoma drainage system 1000 is soft and flexible and does not require the retention of a hollow aqueous humor reservoir inside its aqueous humor diffusion member 1002. A conventional permeable hollow aqueous humor reservoir must therefore be rigid enough to retain its volume. Thus, compared to the glaucoma drainage system 1000, conventional designs are relatively rigid and prone to relative movement between the tissue and the device, and thus tissue irritation that may lead to excessive scarring and erosion of conventional devices.

[0120] As discussed above, in various embodiments, the aqueous humor diffusing member 1002 includes one or more adjacently disposed diffusion membranes having adjacently opposing interfacial surfaces that can slide or otherwise move relative to one another. In some embodiments, aqueous humor discharged from the anterior chamber and introduced into the aqueous humor diffusing member 1002 acts as a lubricant to reduce friction between such interfacial surfaces and further facilitate sliding or relative motion between non-bonded portions or regions. Specifically, as aqueous humor enters the aqueous humor diffusing member 1002, it permeates and diffuses across the various diffusion membranes. As aqueous humor permeates and diffuses across the diffusion membranes, some of the aqueous humor diffuses across the boundaries that separate adjacently disposed diffusion membranes. In some embodiments, as aqueous humor diffuses across the boundaries, it acts as a lubricant to reduce friction between the interfacial surfaces of the boundaries, further increasing the flexibility of the aqueous humor diffusing member 1002.

[0121] As discussed above, in some embodiments, the fluid conduit 1500 is soft and flexible and generally lacks a sufficient amount of structural integrity (e.g., hoop strength) to avoid collapsing under its own weight. In some embodiments, this lack of structural integrity results in deformation of the fluid conduit 1500 to the extent that the lumen extending therethrough loses a significant portion of its cross-sectional area. In some embodiments, this lack of structural integrity causes the fluid conduit 1500 to deform to the extent that aqueous humor in the anterior chamber is also significantly restricted from entering the lumen of the fluid conduit 1500. In some embodiments, to avoid these potential risks, the fluid conduit 1500 may be configured such that one or more of its ends are sufficiently structurally sound in that they are operable to maintain lumen integrity and avoid collapse or significant deformation of the lumen. In such embodiments, the intermediate portion of the fluid conduit 1500 located between the first and / or second ends 1502 and 1504 is generally not structurally sound in that it cannot support its own weight. For example, the end (or terminal portion) of the fluid conduit 1500 that is disposed within the anterior chamber is configured to be operable to maintain luminal integrity and avoid collapse or otherwise significant deformation of the lumen. In this example, the above-mentioned risks associated with relative motion and tissue irritation due to stiffness are generally avoided because the structurally sound end of the fluid conduit 1500 is suspended within the aqueous humor of the anterior chamber and therefore does not interact with tissue in a manner that could cause tissue irritation.

[0122] In various embodiments, the material of the fluid conduit 1500 can undergo one or more material conditioning processes to achieve structurally sound first and / or second ends. In some embodiments, one or more structural members, such as one or more stents or struts or reinforcing rings, can be incorporated, integrated or bonded to the first and / or second ends 1502 and 1504 to achieve the structural integrity described above. These stents, struts and / or reinforcing rings can be formed from any suitable biocompatible metallic or polymeric material discussed herein (e.g., FEP). In some embodiments, localized densification of the first and / or second ends 1502 and 1504 of the fluid conduit 1500 can increase its structural integrity to a degree sufficient to resist closure forces exerted on the ends by body tissue.

[0123] Although the aqueous humor diffusing member 1002 shown and described herein includes a body defined by four diffusion membranes, alternatively, the body of the aqueous humor diffusing member 1002 may be defined by only three diffusion membranes or more than four diffusion membranes without departing from the spirit or scope of the present disclosure. For example, while the above embodiment includes an aqueous humor diffusing member 1002 including a plurality of constrictive diffusion membranes and a plurality of proliferative diffusion membranes, in some embodiments, the aqueous humor diffusing member 1002 includes a constrictive diffusion membrane sandwiched between a plurality of proliferative diffusion membranes. For example, referring now to Figures 7A-7B, referring to Figures 7A and 7B, a glaucoma drainage system 7000 is shown including an aqueous humor diffusing member 7002 defined by a first proliferative diffusion membrane 7100, a first constrictive diffusion membrane 7200, and a second proliferative diffusion membrane 7300. As shown, a first constrictive diffusion membrane 7200 is disposed between first and second proliferative diffusion membranes 7100 and 7300. The first constrictive diffusion membrane 7200 is configured to minimize, resist or prevent tissue ingrowth and adhesion, while the first and second proliferative diffusion membranes 7100 and 7300 are configured to permit tissue ingrowth and adhesion. Figure 7A shows the glaucoma drainage system 7000 in a contracted state. Figure 7B shows the glaucoma drainage system 7000 in an inflated state, with aqueous humor present in an expandable or expandable reservoir 7010 defined between the first proliferative diffusion membrane 7100 and the first constrictive diffusion membrane 7200. Although the glaucoma drainage system 7000 is shown in FIG. 7B in an expanded state in which the glaucoma drainage system 7000 is not uniformly expanded (e.g., the first proliferative membrane 7100 adopts a generally non-linear configuration, while the second proliferative diffusion membrane 7300 and the constrictive diffusion membrane 7200 are shown in a generally linear configuration), it should be understood that the glaucoma drainage system 7000 can be uniformly deformed (e.g., the second proliferative diffusion membrane 7300 and the constrictive diffusion membrane 7200 can be deformed to mirror the deformation of the first proliferative diffusion membrane 7100). The fluid conduit 7500 can be disposed between the first constrictive diffusion membrane 7200 and one of the first and second proliferative diffusion membranes 7100 and 7300. As shown, the fluid conduit 7500 is disposed between the first constrictive diffusion membrane 7200 and the first proliferative diffusion membrane 7100.The constricting diffusion membrane and the proliferative diffusion membrane may be bonded together along their entire adjacent surface regions, consistent with the discussion above, or may include one or more non-bonded or unbonded areas or regions.

[0124] 7B, the first constricting diffusion membrane 7200 and the first proliferative diffusion membrane 7100 are bonded along their peripheries but include non-bonded or unbonded regions therein to define the reservoir 7010. Thus, the non-bonded or unbonded regions between the first constricting diffusion membrane 7200 and the first proliferative diffusion membrane 7100 can separate from each other as the reservoir 7010 expands or expands as aqueous humor enters the reservoir 7010.

[0125] It should be appreciated that the configuration of the glaucoma drainage system 7000 shown in Figures 7A and 7B includes a reservoir 7010 defined between a stenotic diffusive membrane and a proliferative diffusive membrane. With such a configuration, tissue ingrowth is permitted along one side of the reservoir and tissue ingrowth is minimized, resisted, or prevented along the other side of the reservoir. Furthermore, because the stenotic diffusive membrane and the proliferative diffusive membrane are associated with different permeabilities, the drained aqueous humor will permeate the stenotic diffusive membrane and the proliferative diffusive membrane at different rates.

[0126] In some embodiments, these different rates at which aqueous humor diffuses or penetrates different membranes can be utilized to influence, direct, or otherwise "steer" the aqueous humor through the aqueous humor diffusing member. In some embodiments, the aqueous humor diffusing member can be configured such that a higher percentage (or a higher volume) of aqueous humor is directed toward a first outer surface of the aqueous humor diffusing member than toward a second outer surface of the aqueous humor diffusing member. Similarly, in some embodiments, the aqueous humor diffusing member can be configured such that a portion of the aqueous humor is directed toward the periphery of the aqueous humor diffusing member. Such a configuration can steer the drained aqueous humor toward designated areas of the surrounding tissue, such as areas of the surrounding tissue that are adapted to better absorb the drained aqueous humor and better facilitate its absorption into the tear film.

[0127] For example, with continued reference to Figures 7A and 7B, in some embodiments, the first proliferative diffusion membrane 7100 has a higher flux than the flux of the first constricting diffusion membrane 7200, and thus a higher percentage (or a higher volume) of aqueous humor is steered toward the outer surface extending along the first proliferative diffusion membrane 7100 compared to the percentage (or volume) of aqueous humor that is steered toward the outer surface extending along the second proliferative diffusion membrane 7400. It should be appreciated that in some embodiments, such a configuration may additionally or alternatively be achieved by forming the first constricting diffusion membrane with a higher flux than the flux of the second constricting diffusion membrane. In some embodiments, such a configuration may additionally or alternatively be achieved by forming a boundary between adjacently disposed diffusion membranes such that the different boundaries are associated with different fluxes. The different boundaries associated with the different fluxes can be achieved by the way in which adjacently disposed diffusion films are adhered or bonded to one another.

[0128] 7A and 7B includes a fluid conduit 7500 disposed between the first proliferative diffusion membrane 7100 and the first constricting diffusion membrane 7200, and a reservoir 7010 defined between the first proliferative diffusion membrane 7100 and the first constricting diffusion membrane 7200, it should be understood that the first constricting diffusion membrane may be formed from multiple laminated layers of polymeric material (as described above) and the fluid conduit 7500 may be disposed between adjacent layers of polymeric material. Additionally or alternatively, in some instances, one or more adjacent opposing layers of polymeric material forming the constricting membrane may include one or more non-bonded, non-bonded or non-laminated areas or regions, consistent with the discussion above, whereby the non-bonded, non-bonded or non-laminated areas or regions of the adjacent opposing layers of polymeric material are free to be separated from one another and slide or move relative to one another to at least partially define the reservoir 7010.

[0129] Although the aqueous humor diffusing members illustrated and described herein are generally thin, flat, and circular (or oval), it should be understood that the aqueous humor diffusing members may be of any suitable shape without departing from the spirit or scope of the present disclosure. For example, the aqueous humor diffusing members may be square, rectangular, trapezoidal, or other polygonal, may include chamfered or rounded edges between the sides, and the sides may be essentially straight or generally curved. Alternatively, the aqueous humor diffusing members may have a substantially continuous curved edge in that they are circular or oval, or another suitable shape (e.g., bean-shaped). Thus, the embodiments and examples contained herein should not be construed as limiting, and one of ordinary skill in the art will understand that the aqueous humor diffusing members may be of any desired shape, so long as they are useful in containing the discharged aqueous humor to a sufficient extent and facilitating the reabsorption of the aqueous humor to constitute an effective treatment for the patient.

[0130] In some alternative embodiments, the aqueous diffusion member can have a tubular or cylindrical profile including multiple diffusion membranes arranged concentrically. For example, the aqueous diffusion member can include a tubular constrictive diffusion membrane and a tubular proliferative diffusion membrane, where the tubular constrictive diffusion membrane corresponds to an inner diffusion membrane concentric with the proliferative diffusion membrane, and the proliferative diffusion membrane defines the exterior of the aqueous diffusion member. Now, referring to FIG. 8, a glaucoma drainage system 8000 is shown including an aqueous diffusion member 8002 defined by an outer tubular proliferative diffusion membrane 8100 that is concentric with an inner tubular constrictive diffusion membrane 8200. A portion of the aqueous diffusion member 8002 is shown cut away to expose an interior region of the aqueous diffusion member 800. As shown, a reservoir 8010 is defined within a central lumen of the inner tubular constricting diffusion membrane 8200, and a fluid conduit 8500 is fluidly coupled to the reservoir 8010 at a second end 8006 of the aqueous humor diffusing member 8002. In some embodiments, the concentric diffusion membranes of the aqueous humor diffusing member 8002 shown in FIG. 8 can be unbonded or partially unbonded to one another, as discussed herein. In some embodiments, at least one end of the aqueous humor diffusing member 8002 (e.g., the first end 8004 opposite the fluid conduit 8500) is sealed to allow draining aqueous humor to permeate through the concentric diffusion membranes of the aqueous humor diffusing member 8002.

[0131] As mentioned above, in various embodiments, the fluid conduit is a soft, malleable tubular member that can be inserted into the anterior chamber of the eye. Generally, regardless of the particular surgical approach employed by the physician, one or more of the fluid conduits and the aqueous humor diffusion member are advanced or pushed during the implantation procedure. Soft, thin, malleable tubular structures are generally difficult to advance through tissue. Thus, in various embodiments, the glaucoma drainage system described herein can further include a stiffening member removably integrated with the glaucoma drainage system. The removable stiffening member operates with the fluid conduit to temporarily form a placement assembly having a column strength that exceeds the column strength of the fluid conduit. For example, in some embodiments, the stiffening member is disposed within the fluid conduit. In some other embodiments, the stiffening member is additionally or alternatively disposed around the fluid conduit. The treatment method can include utilizing the stiffening member to advance one or more of the fluid conduits and the aqueous humor diffusion member into position, and then removing the stiffening member after implantation.

[0132] Additionally or alternatively, in various embodiments, the fluid conduits of the various glaucoma drainage systems discussed herein may be configured such that they include multiple lumens. In some embodiments, one or more lumens of a multi-lumen fluid conduit may be initially blocked, and one or more lumens of a multi-lumen fluid conduit may be unblocked post-operatively to increase the fluid flow rate through the fluid conduit. Thus, in various embodiments, the various glaucoma drainage systems described herein may include one or more mechanisms that may be modified post-operatively to increase and / or decrease the aqueous humor transmission rate per unit time of the glaucoma drainage system. Thus, the glaucoma drainage systems described herein are operable to dynamically change to accommodate changes in the anatomy or function of the patient's eye post-operatively, without the need for additional invasive surgery.

[0133] In some embodiments, the glaucoma drainage system discussed herein is implanted ab-internally (e.g., from the inside of the eye), such as through a clear corneal incision, and placed through the sclera into the incised subconjunctival space, as will be understood by those of skill in the art. In other embodiments, the glaucoma drainage system can be implanted externally (e.g., from the outside of the eye), such as through a conjunctival incision, as will be understood by those of skill in the art. In some embodiments, a radial incision in the conjunctiva is made, typically near the limbal junction, and blunt dissection of the conjunctiva is performed to expose the sclera and provide a site for placement of the aqueous humor diffusion member. In some embodiments, this may require suturing the aqueous humor diffusion member to the sclera. In some embodiments, a small needle, typically a 22-gauge or 23-gauge needle, is also inserted near the scleral spine to provide a trajectory for subsequent insertion and placement of a fluid conduit into the anterior chamber.

[0134] As mentioned above, in various embodiments, the aqueous humor diffusing member discussed herein is formed from a plurality of diffusion membranes, including a proliferative diffusion membrane and a constrictive diffusion membrane, where the porosity or permeability to aqueous humor of the proliferative diffusion membrane exceeds the porosity of the constrictive diffusion membrane. Thus, the disclosed aqueous humor diffusing member includes a plurality of different membranes having different degrees of porosity (e.g., different amounts of pores and / or pores having different sizes). In general, different diffusion membranes having different porosity are associated with different rates (also called fluxes) at which aqueous humor diffuses to the associated membrane. For example, the aqueous humor diffusing member may be configured such that an amount of aqueous humor diffuses to the constrictive diffusion membrane at a different rate (e.g., lower flux) than an amount of aqueous humor diffuses to the proliferative diffusion membrane (e.g., higher flux). Thus, the aqueous humor diffusing member may be configured such that aqueous humor diffuses to a first region of the aqueous humor diffusing member at a different rate than aqueous humor diffuses to a second region of the aqueous humor diffusing member.

[0135] As described above, in various embodiments, the layers of polymeric material forming the diffusion membrane can be bonded together at one or more distinct locations to form a stabilizing structure extending through the diffusion membrane. In some embodiments, during the lamination process, the various layers forming the diffusion membrane can be laminated together such that one or more distinct pillars or columnar structures extend through the diffusion membrane from a first interface surface of the diffusion membrane to a second interface surface of the diffusion membrane. In various embodiments, these pillars or columnar structures can be formed with an adhesive. In some embodiments, one or more of these pillars can effectively leave open or otherwise maintain an effective strainable, shearable, slidable interface so that the glaucoma drainage device is flexible and operable to accommodate the drained aqueous humor. Furthermore, in some embodiments, unintended expansion (e.g., ballooning) of the aqueous humor diffusion member beyond a specified amount or beyond a specified profile can be minimized and / or avoided by individually bonding adjacently facing interface surfaces of adjacently disposed diffusion membranes, as described above.

[0136] As discussed above, in various embodiments, the fluid conduits and / or body of the aqueous humor diffusion member are formed from a soft, malleable material to create a structure that conforms to the curvature of the eye and helps minimize relative movement between the glaucoma drainage system and surrounding tissue that may cause tissue irritation, foreign body tissue reaction, excessive scarring and / or erosion. Another potential problem experienced with conventional designs includes erosion of the fluid conduits through the conjunctiva, which is typically in close proximity to the area where the fluid conduits extend through the sclera into the anterior chamber of the eye. Such erosion of the conjunctiva can lead to direct exposure of the anterior chamber, providing a pathway for bacteria to enter the eye, risk of endophthalmitis, and potential loss of vision in the eye.

[0137] Many approaches have been attempted to minimize the likelihood of such erosion through the conjunctiva, but none of the known solutions include a single device or system that combines aqueous humor drainage with protection from erosion of the fluid conduits.

[0138] 9A-11, in various embodiments, a glaucoma drainage system 9000 includes an aqueous humor diffusing member 9002 and a fluid conduit 9500. The fluid conduit 9500 may be consistent in structure, form, configuration, and function with the various fluid conduits described above (e.g., fluid conduit 1500). Similarly, the aqueous humor diffusing member 9002 may be consistent in structure, form, configuration, and function with the various aqueous humor diffusing members described above (e.g., aqueous humor diffusing member 1002), with the exception that the aqueous humor diffusing member 9002 further includes one or more erodible elements 9600.

[0139] In various embodiments, the erosion element 9600 is an element, feature, component or portion of the glaucoma drainage system 9000 that covers a portion of the fluid conduit 9500 and helps minimize erosion of the fluid conduit 9500 through one or more tissues of the eye when the glaucoma drainage system 9000 is implanted. As discussed above, in various embodiments, the glaucoma drainage system 9000 is implantable within a pocket formed between the conjunctiva and the sclera of the eye, as will be understood by one of ordinary skill in the art.

[0140] In some cases, for example, the erosion element 9600 extends from the body of the glaucoma drainage system 9000 to cover the fluid conduit 9500. The erosion element 9600 acts as a protective barrier between the fluid conduit 9500 and one or more surrounding tissues of the eye. For example, the glaucoma drainage system 9000 can be configured such that when implanted, the erosion element 9600 extends along the fluid conduit 9500 between the fluid conduit 9500 and the conjunctiva of the eye. In some such embodiments, the erosion element 9600 helps to minimize or even prevent erosion of the fluid conduit 9500 through the conjunctiva by forming a barrier between the fluid conduit 9500 and the conjunctiva when the glaucoma drainage device 9000 is implanted in the eye, as discussed further below.

[0141] In some embodiments, the erosion element 9600 forms an integral, inseparable element, feature, component, or portion of the glaucoma drainage system 9000. In some other embodiments, the erosion element 9600 is formed as a separate element or component that is coupled to one or more portions of the glaucoma drainage system 9000. In some such embodiments, the erosion element 9600 may be coupled to one or more portions of the glaucoma drainage system 9000, thereby making it integral with the glaucoma drainage system 9000. Alternatively, in some embodiments, the erosion element 9600 may be coupled to one or more portions of the glaucoma drainage system 9000 such that the erosion element 9600 can be subsequently separated and removed from the glaucoma drainage system 9000.

[0142] As noted above, the glaucoma drainage system 9000 can include multiple erosion elements 9600. In some such embodiments, the fluid conduit 9500 of the glaucoma drainage system 9000 can be isolated from interfacing with surrounding eye tissue (e.g., the sclera or conjunctiva) by incorporating multiple erosion elements 9600. That is, in some embodiments, the glaucoma drainage system 9000 can include one or more erosion elements 9600 that isolate the fluid conduit 9500 of the glaucoma drainage system 9000 from eye tissue. For example, the glaucoma drainage system 9000 can be configured such that the erosion elements 9600 are adjacent to the fluid conduit 9500 on either side of a plane that bisects the fluid conduit 9500 along its longitudinal axis. In such a configuration, for example, a first erosion element of the erosion element 9600 can extend along the fluid conduit 9500 between the fluid conduit 9500 and the sclera of the eye. Similarly, a second erosion element of the erosion element 9600 can extend along the fluid conduit 9500 between the fluid conduit 9500 and the conjunctiva of the eye. Such a configuration provides erosion protection to both the conjunctiva and sclera of the eye because it prevents the glaucoma drainage device 9000 from directly interfacing with the conjunctiva and sclera of the eye when implanted in the eye (e.g., when implanted in a pocket formed between the conjunctiva and sclera).

[0143] As mentioned above, with the exception of the erosion element 9600, the glaucoma drainage system 9000 is similar in structure, form and configuration to other glaucoma drainage systems discussed herein (e.g., glaucoma drainage system 1000). Thus, in various embodiments, the glaucoma drainage system 9000 includes a multi-layer structure and is configured to facilitate drainage of aqueous humor from within the anterior chamber of the eye, as well as aid in drainage of aqueous humor from the anterior chamber of the eye, for example, by facilitating reabsorption of the drained aqueous humor by the body. Similar to the glaucoma drainage system 1000, in various embodiments, the glaucoma drainage system 9000 also includes one or more constrictive diffusion membranes and one or more proliferative diffusion membranes arranged to optimize aqueous humor drainage and reabsorption (see discussion above).

[0144] In various embodiments, the erodible element 9600 comprises a thin, flexible porous membrane that is consistent in structure, form, and configuration with various other thin, flexible porous membranes discussed herein (e.g., the diffusion membranes discussed above). For example, the erodible element 9600 can comprise a microstructure configured to resist tissue ingrowth (e.g., a constrictive diffusion membrane) or can comprise a microstructure configured to promote or tolerate tissue ingrowth (e.g., a proliferative diffusion membrane). Alternatively, in some embodiments, the erodible element 9600 can comprise a multi-layer structure that includes a first membrane configured to promote or tolerate tissue ingrowth (e.g., a proliferative diffusion membrane) and a second membrane configured to resist tissue or cell ingrowth (e.g., a constrictive diffusion membrane). The permissive / resistant membranes in such embodiments are oriented to optimize their effectiveness when the glaucoma drainage device 9000 is implanted in an eye. For example, as described in more detail below, in various embodiments, the eroding element 9600 is configured to promote or allow tissue ingrowth along an interface between the eroding element 9600 and an ocular tissue (e.g., the sclera or conjunctiva, etc.) Thus, it will be understood that the material of the eroding element 9600 can include any material and can be constructed according to any method discussed herein as suitable for the diffusion membrane described above.

[0145] Thus, in various embodiments, the erosion element 9600 may be coupled to (or alternatively may be an extension of or integral with) any of the various proliferative or constrictive diffusion membranes discussed herein. Thus, in some embodiments, the erosion element 9600 may itself be a constrictive diffusion membrane (e.g., configured to minimize, resist, or prevent tissue ingrowth) or a proliferative diffusion membrane (e.g., configured to permit tissue ingrowth). In some such embodiments, the erosion element 9600 is a constrictive diffusion membrane coupled to or integral with a constrictive diffusion membrane of an aqueous humor diffusing member. Additionally or alternatively, in some embodiments, the erosion element 9600 is a constrictive diffusion membrane coupled to a proliferative diffusion membrane of an aqueous humor diffusing member. In some embodiments, the erosion element 9600 is a proliferative diffusion membrane coupled to a constrictive diffusion membrane of an aqueous humor diffusing member. In some embodiments, the erodible element 9600 is a proliferative diffusing membrane that is coupled to or integral with the proliferative diffusing membrane of the aqueous humor diffusing member.

[0146] 9A-9C and 10, a glaucoma drainage system 9000 is shown. FIG. 9A is a top view of the glaucoma drainage system. FIG. 9B is a cross-sectional view of the glaucoma drainage system 9000 taken along line 9B-9B in FIG. 9A. FIG. 9C is a cross-sectional view of the glaucoma drainage system 9000 taken along line 9C-9C in FIG. 9A. FIG. 10 is an exploded view of the glaucoma drainage system 9000.

[0147] As shown, the glaucoma drainage system 9000 includes an aqueous humor diffusion member 9002, a fluid conduit 9500 (e.g., a shunt), and an erodible element 9600. The aqueous humor diffusion member 9002 includes multiple layers including a first layer 9010 and a second layer 9020. The first and second layers 9010 and 9020 each include one or more diffusion membranes configured to promote or allow tissue ingrowth (e.g., a proliferative diffusion membrane) and / or one or more diffusion membranes configured to resist tissue ingrowth (e.g., a constrictive diffusion membrane). Thus, it will be appreciated that the first layer 9010 can include one or more diffusion membranes configured to promote or allow tissue ingrowth and one or more diffusion membranes configured to minimize, resist, or prevent tissue ingrowth. Similarly, it will be appreciated that the section layer 9020 may additionally or alternatively be formed from one or more diffusion membranes configured to promote or allow tissue ingrowth, and one or more diffusion membranes configured to minimize, resist or prevent tissue ingrowth. Accordingly, it will be appreciated that the aqueous humor diffusing member 9002 may be similar in structure, form and function to various other aqueous humor diffusing members discussed herein.

[0148] 9A-12, the glaucoma drainage system 9000 includes an erosion element 9600. The erosion element 9600 extends away from the aqueous humor diffusing member 9002 of the glaucoma drainage system 9000 as shown. In some embodiments, the erosion element 9600 extends away from the aqueous humor diffusing member 9002 along the fluid conduit 9500 between the fluid conduit 9500 and the aqueous humor diffusing member 9002. In some embodiments, the erosion element 9600 extends between the aqueous humor diffusing member 9002 and an end of the fluid conduit 9500 (e.g., a first end or a second end of the fluid conduit 9500) and is configured to access a body cavity filled with a biological fluid, such as the anterior chamber of the eye, among other embodiments, as will be appreciated by those skilled in the art.

[0149] 9A-9C and 10 as including a rectangular shape, it will be understood that the eroding element 9600 may be of any suitable shape without departing from the spirit or scope of the present disclosure. For example, the eroding element 9600 may be a square, rectangular, trapezoidal, or other polygonal shape, may include chamfered or rounded edges between the sides, and the sides may be essentially straight or generally curved. The eroding element 9600 may have a generally continuous curved edge in that it is circular or oval, or another suitable shape (e.g., bean-shaped). One skilled in the art will understand that the eroding element 9600 may be of any desired shape, so long as the eroding element 9600 serves to protect the fluid conduit from erosion through the surrounding tissue as described herein, and the eroding element 9600 may be disposed within the subconjunctival space (such as a pocket formed between the conjunctiva and the sclera).

[0150] In some embodiments, the eroding element 9600 extends along the length of the fluid conduit but includes a length that is less than the length of the portion of the fluid conduit that extends from the aqueous humor diffusion member 9002. In other embodiments, the eroding element 9600 extends along the length of the fluid conduit but includes a length that is greater than or equal to the length of the portion of the fluid conduit that extends from the aqueous humor diffusion member 9002. In some embodiments, the eroding element 9600 has a width that is greater than or equal to the diameter of the fluid conduit 9500. However, in some embodiments, the width of the eroding element 9600 may be less than the diameter of the fluid conduit, so long as the eroding element 9600 is not ineffective in assisting in protecting the fluid conduit against erosion through the surrounding tissue. Consistent with the variety of suitable sizes and shapes of the eroding element 9600 discussed above, it will be appreciated that the width of the eroding element 9600 may remain constant along the length of the eroding element 9600 or, alternatively, the width of the eroding element 9600 may vary along the length of the eroding element 9600. For example, the eroding element may taper in width (linearly or non-linearly) along its longitudinal length.

[0151] In some embodiments, the erosion element 9600 can be configured to be more wear resistant in high wear or high wear regions (e.g., regions where the fluid conduit 9500 may move relative to the erosion plate 9600). Wear resistance in such regions can be achieved according to any known method, including material composition and / or material thickness. Thus, the thickness of the erosion element 9600 can vary along the length of the erosion element 9600 and / or can vary laterally across its width. For example, the thickness can taper (linearly or non-linearly) along the length of the erosion element 9600 and / or transversely across it. For example, the thickness of the erosion element 9600 along a longitudinally extending centerline can exceed the thickness of the erosion element 9600 along one or more longitudinally extending edges. Alternatively, it will be appreciated that the thickness of the erosion element 9600 along a longitudinally extending centerline can be less than the thickness of the erosion element 9600 along one or more longitudinally extending edges. Additionally or alternatively, the thickness of the erosion element 9600 along a section of its longitudinal length can be greater than the thickness of the erosion element 9600 along a second section of its longitudinal length. For example, a section of the erosion element 9600 closer to an end of the fluid conduit 9500 configured to access the fluid-filled body cavity can be thicker than a section of the erosion element 9600 closer to the aqueous humor diffusion member 9002, where the region where the fluid conduit 9500 accesses the fluid-filled body cavity corresponds to a high wear region. It should be appreciated that the thickness of the erosion plate 9600 can be optimized in high wear or high friction regions to reduce the risk of premature failure of the glaucoma drainage system 9000 due to wear of the erosion plate 9600 by the fluid conduit 9500. These variations in thickness can be achieved by selective layering of the materials that collectively form the erosion element 9600 or other known methods.

[0152] In some embodiments, the erosion element 9600 can be spaced longitudinally from the aqueous humor diffusion member 9002 or can include a region of reduced width (e.g., as shown in FIG. 10 ) and / or thickness (not shown) that extends along a region of the fluid conduit 9500 between the erosion element 9600 and the aqueous humor diffusion member 9002 that has a low risk of eroding through the surrounding tissue. For example, if a portion of the fluid conduit 9500 adjacent the aqueous humor diffusion member 9002 has a low risk of eroding the surrounding tissue, the region of reduced width and / or thickness of the erosion element 9600 can be located adjacent this region of the fluid conduit 9500. Alternatively, the erosion element 9600 can be configured such that the fluid conduit 9500 is exposed to the surrounding tissue in this region of low risk of erosion. Thus, in some examples, the erosion element 9600 may not extend from the aqueous humor diffusion member 9002.

[0153] In some embodiments, the erodible element 9600 is coupled to the fluid conduit 9500. The erodible element 9600 may be coupled to the fluid conduit 9500 continuously along the length of the fluid conduit 9500 or at one or more discrete locations along the fluid conduit 9500. The erodible element 9600 may be coupled to the fluid conduit 9500 according to any known method, including but not limited to, sewing or suturing the erodible element along the length of the conduit. In some embodiments, the stitching can be a series of intermittent stitches or a continuous suturing stitch. Additionally or alternatively, the fluid conduit 9500 can be mechanically bonded to the erodible element 9600 by partially dissolving the fluid conduit 9500 into the microporous structure of the erodible element 9600. In some embodiments, the erodible element 9600 can be coated with a tacky adhesive such that the fluid conduit 9500 can be releasably attached to the erodible element 9600. In some embodiments, one or more bands of material (e.g., microporous material) can have ends bonded to the erodible element 9600 such that an eyelet is formed between the material bands and the erodible element 9600, and the fluid conduit 9500 can be passed through the gap.

[0154] As discussed above, when used to treat conditions such as glaucoma, the glaucoma drainage system 9000 may be positioned within the subconjunctival space (e.g., a pocket formed between the conjunctiva and sclera of the eye). The glaucoma drainage system 9000 adopts a relatively flat, minimal radial profile within the subconjunctival space and is positioned such that the anterior chamber of the eye is accessible by the fluid conduit 9500. Now, with reference to Figures 11 and 12, the glaucoma drainage system is illustrated in an implanted configuration. Figure 11 includes a glaucoma drainage system 9000 having an aqueous humor diffusing member 9002, a fluid conduit 9500, and an erosion element 9600. Figure 12 includes a glaucoma drainage system 9000 having an aqueous humor diffusing member 9002, a fluid conduit 9500, and a plurality of first and second erosion elements 9600A and 9600B.

[0155] 11, for example, the glaucoma drainage system 9000 is shown disposed in the subconjunctival space 2006 between the conjunctiva 2002 and the sclera 2004 of the eye 2000. The glaucoma drainage system 9000 is shown oriented such that the first layer 9010 extends along the sclera 2004 and the second layer 9020 extends along the conjunctiva 2002. It will be appreciated that the portion of the second layer 9020 that interfaces with the conjunctiva 2002 may be configured to promote or allow tissue ingrowth, as discussed above. It will also be appreciated that the portion of the first layer 9010 that interfaces with the sclera may additionally or alternatively be configured to promote or allow tissue ingrowth, as discussed above. Such a configuration helps to minimize relative movement between the aqueous humor diffusion member 9002 and the surrounding tissue.

[0156] 11 as extending from the aqueous humor diffusion member 9002 and through a scleral access, perforation or hole 2008 (e.g., made by a physician during an implantation procedure according to known methods), whereby the first end 9502 accesses the anterior chamber (AC). Additionally, as shown, the erosion element 9600 extends between the fluid conduit 9500 and the conjunctiva 2002 of the eye 2000. In particular, the erosion element 9600 extends between the fluid conduit 9500 and the conjunctiva 2002 such that a portion of the erosion element 9600 is disposed adjacent or proximate to the scleral access 2008 and / or adjacent or proximate to a portion 9506 of the fluid conduit that extends through the scleral access 2008. Such a configuration provides that the conjunctiva 2002 is not directly exposed to the fluid conduit 9500. Instead, as shown, the erosion element 9600 extends along the conjunctiva 2002. This configuration helps protect against erosion of the fluid conduit 9500 through the conjunctiva 2002 as the erosion element 9600 acts as a protective barrier between the conjunctiva 2002 and the fluid conduit 9500. For example, the erosion element 9600 acts as a protective barrier between a fluid conduit and a portion of the conjunctiva 2010 that is located adjacent or proximate to the scleral access 2008, as shown.

[0157] It will be appreciated that the portion of the eroding element 9600 that interfaces with the conjunctiva 2002 can be configured to promote or allow tissue ingrowth, as described above. Such a configuration helps to minimize relative motion between the eroding element 9600 and the conjunctiva, even if there may be relative motion between the fluid conduit 9500 and the eroding element 9600.

[0158] Although the erosion element 9600 is shown in FIG. 11 as including a portion that extends beyond the scleral access 2008 (and thus the portion of the fluid conduit 9500 that extends through the scleral access), in some embodiments, the erosion element 9600 can extend all the way to the scleral access 2008 or less, so long as the erosion element 9600 is not rendered ineffective in helping to protect against erosion.

[0159] In some embodiments, upon implantation, aqueous humor enters the first end 9502 of the fluid conduit 9500 and travels to the second end 9504 of the fluid conduit, which is in fluid communication with the aqueous humor diffusing member 9002. In some embodiments, the second end 9504 is disposed within the aqueous humor diffusing member 9002, in a manner similar to that described above with respect to the second end 1504 of the fluid conduit 1500 and the aqueous humor diffusing member 9002. Thus, as described above, the drained aqueous humor enters the reservoir defined within the aqueous humor diffusing member 9002 and permeates through the various diffusion membranes of the aqueous humor diffusing member 10002, where it can be absorbed by the surrounding and / or ingrown tissue.

[0160] Referring now to Figure 12, a glaucoma drainage system 9000 is shown disposed in the subconjunctival space 2006 between the conjunctiva 2002 and the sclera 2004 of the eye 2000. The configuration of the glaucoma drainage system 9000 shown in Figure 12 is similar to the configuration of the glaucoma drainage system 10000 shown in Figure 11, except that the glaucoma drainage system 9000 shown in Figure 12 includes two erosion elements (e.g., a first erosion element 9600A and a second erosion element 9600B). The first erosion element 9600A corresponds in structure, form and function to the erosion element 9600 described above with respect to Figure 11. 12 includes a second erosion element 9600B in combination with a first erosion element 9600A, it will be understood that a glaucoma drainage system can include the second erosion element 9600B without the need for a first erosion element 9600A. That is, in some embodiments, the glaucoma drainage system 9000 can be configured to include an erosion element extending between the fluid conduit 9500 and the sclera 2004 without the need for an erosion element extending between the fluid conduit 9500 and the conjunctiva 2002.

[0161] 12, the fluid conduit 9500 extends through the opening 9602B of the second eroding element 9600B before extending through the scleral access, perforation or hole 2008 (e.g., made by the physician according to known methods during the implantation procedure) and into the anterior chamber (AC). Thus, it will be understood that in various embodiments, the eroding element (e.g., the second eroding element 9600B) can include one or more incisions, perforations or openings configured to accommodate the fluid conduit 9500. In some embodiments, the second eroding element 9600B is constructed or manufactured with such pre-formed openings. In some other embodiments, the incisions, perforations or openings can be formed in the eroding element during or immediately prior to the implantation procedure. In some embodiments, the incisions, perforations or openings are formed by the physician or a physician's assistant.

[0162] As shown, the second eroding element 9600B extends between the fluid conduit 9500 and the sclera 2004, while the first eroding element 9600A extends between the fluid conduit 9500 and the conjunctiva 2002. Although the second eroding element 9600B shown in FIG. 12 includes an opening 9602B and thus extends partially beyond the scleral access 2008, it will be understood that the second eroding element 9600B may not extend to or beyond the scleral access 2008 and thus may not require an opening 9602B. In such a configuration, the second eroding element 9600B may extend between the sclera 2004 and the fluid conduit 9500 to a position short of the scleral access 2008 (not shown).

[0163] A configuration including an erodible element positionable between the fluid conduit 9500 and the sclera 2004 provides that the sclera 2004 is not directly exposed to the fluid conduit 9500. Such a configuration helps protect against erosion of the fluid conduit 9500 through the sclera 2004, as such an erodible element acts as a protective barrier between the sclera 2004 and the fluid conduit 9500.

[0164] In some embodiments, the portion of the second eroding element 9600B that interfaces with the sclera 2004 can be configured to promote or allow tissue ingrowth, as described above. Such a configuration helps to minimize relative motion between the second eroding element 9600B and the sclera 2004, even if there may be relative motion between the fluid conduit 9500 and the second eroding element 9600B.

[0165] In various embodiments, one or more portions of the glaucoma drainage systems discussed herein may include or be coated with one or more therapeutic agents, such as one or more glaucoma medications, as will be appreciated by one of skill in the art. Additionally or alternatively, in various embodiments, one or more portions of the glaucoma drainage systems discussed herein may include one or more markers (e.g., radiopaque markers) for visually or electronically determining proper placement of the glaucoma drainage system within the anatomy.

[0166] In various embodiments, the diffusion membrane material can additionally or alternatively undergo one or more processes (e.g., denucleation) to remove air trapped within various voids within the material. It is understood that these processes can be combined with one or more of the hydrophilic coating processes described above. Trapped air can sometimes prevent the wetting or infiltration of the material by aqueous humor, which can impair the efficiency of aqueous humor diffusing into the aqueous humor diffusion member and being reabsorbed by the body. In some embodiments, the trapped air can be removed by immersing the material in a series of baths. In some embodiments, these baths can progress from one or more alcohol baths to one or more sterile water baths. EXAMPLES

[0167] Example 1 The medical device was constructed according to the following method: A bottom sacrificial compression layer of thick expanded PTFE tape was prepared by laser cutting a small coupon of PTFE expanded tape. In particular, the shape of the glaucoma drainage device laser cut from the sacrificial PTFE layer corresponded to the shape of the first layer 9010 shown in FIG. 10. All chads were removed and the sacrificial layer was aligned and placed in a jig plate configured to accommodate the small coupon. A first coupon of microporous diffusion material (e.g., multi-layer ePTFE) was then placed on top of the small coupon of sacrificial PTFE material. The shape of the glaucoma drainage device was not laser cut into the first coupon of microporous diffusion material. The first coupon of microporous diffusion material was oriented such that the tissue ingrowth side of the first coupon of microporous diffusion material was facing downward toward the sacrificial PTFE coupon.

[0168] A layer of adhesive film (e.g., FEP) was then prepared by laser cutting the shape of the glaucoma drainage device into the adhesive film that was the same size and location as that laser cut in the sacrificial PTFE coupon. All chads were then removed and the adhesive film layer was aligned and placed over the microporous diffusive material so that the adhesive film lay flat with no wrinkles or folds. A second coupon of microporous diffusive material (e.g., multi-layer ePTFE) was then placed over the adhesive film. The shape of the glaucoma drainage device was not laser cut into the second coupon of microporous diffusive material. The second coupon of microporous diffusive material was oriented so that the tissue ingrowth side of the second coupon of microporous diffusive material was facing up and away from the adhesive film. A top sacrificial compression layer of thickly expanded PTFE tape was then placed over the second coupon of microporous diffusive material. The shape of the glaucoma drainage device was not laser cut into the top sacrificial compression layer of thickly expanded PTFE tape. In this construction of the laminated stack, the jig was compressed such that the first and second coupons of microporous diffusive material were uniformly compressed, except for the laser cut areas corresponding to the size and shape of the glaucoma drainage device. That is, when the cutout of the shape of the glaucoma drainage device was made in the first lower sacrificial layer, only minimal force was applied to the area corresponding in size and shape to the glaucoma drainage device, which was insufficient to form a bond between the first and second coupons of microporous diffusive material. Similarly, no adhesive film was applied to the corresponding areas of the first and second coupons of microporous diffusive material, because the chads corresponding to the size and shape of the glaucoma drainage device were removed from the adhesive layer during the lay-up process.

[0169] The jig and layup were then placed onto a heated press plate, such as a desktop hot press, preheated to about 280° C., and compressed sufficiently for a designated period of at least 5 minutes to create a bond between the first and second coupons of microporous diffusive material and the adhesive film, while avoiding significant bonding of the laminate to the sacrificial layer. The laminate was then removed from the press and allowed to cool to room temperature.

[0170] The resulting laminate was then laser cut to final size. In particular, the cut lines followed a tracing of the glaucoma drainage device shape formed in the first sacrificial layer of PTFE, with the periphery of the device shape offset a short distance (approximately 1 mm) outward to include portions of the first and second coupons of microporous diffusive material bonded together.

[0171] A fluid conduit formed from silicone tubing was inserted between the non-compressible layers and routed to the interior of the glaucoma drainage device by slightly separating the non-compressible layers and inserting the tubing up to the inner circumference defined by the first and second coupons of microporous diffusive material joined together. The tubing was then secured to the glaucoma drainage device according to known methods.

[0172] Example 2 The medical device was constructed according to the following method: A bottom sacrificial compression layer of thick expanded PTFE tape was prepared by laser cutting a small coupon of PTFE expanded tape. A glaucoma drainage device shape consistent with the above was laser cut from the small coupon with approximately 8 mm circular dimensions. In particular, the glaucoma drainage device shape laser cut from the small coupon corresponded to the shape of the second layer 9020 shown in FIG. 10. That is, the glaucoma drainage device shape laser cut from the small coupon included an oval aqueous humor diffusion region and a rectangular erosion element consistent with the above. All chads were removed and the sacrificial layer was aligned and placed in a jig plate configured to accommodate the small coupon. A first coupon of microporous diffusion material (e.g., multi-layer ePTFE) was then placed on top of the small coupon of sacrificial PTFE material. The glaucoma drainage device shape was not laser cut into the first coupon of microporous diffusion material. The first coupon of microporous diffusion material was oriented such that the tissue ingrowth side of the first coupon of microporous diffusion material faced downward toward the sacrificial PTFE coupon.

[0173] A layer of adhesive film (e.g., FEP) was then prepared by laser cutting the shape of the glaucoma drainage device, excluding the rectangular erosion element feature, into the adhesive film that was identical in size and location to that laser cut in the sacrificial PTFE coupon (but excluding the rectangular erosion element feature). In particular, the shape of the glaucoma drainage device laser cut from the adhesive film corresponded to the shape of the first layer 9010 shown in FIG. 10. All chads were then removed and the adhesive film layer was aligned and placed on top of the microporous diffusion material so that the adhesive film was flat without wrinkles or folds. A second coupon of microporous diffusion material (e.g., multi-layer ePTFE) was then placed on the adhesive film. The shape of the rectangular erosion element was laser cut into a second coupon of microporous diffusion material that was identical in size and location to that laser cut in the sacrificial PTFE coupon. All chads were then removed and the second coupon of microporous diffusion material was oriented so that the tissue ingrowth side of the second coupon of microporous diffusion material was facing up and away from the adhesive film.

[0174] The top sacrificial compression layer of thickly expanded PTFE tape was then placed over the second coupon of microporous diffusion material. The shape of the glaucoma drainage device was not laser cut into the top sacrificial compression layer of thickly expanded PTFE tape. In this laminated stack configuration, the jig was compressed to uniformly compress the first and second coupons of microporous diffusion material, except for the laser cut areas corresponding to the size and shape of the glaucoma drainage device that was cut into the first sacrificial layer.

[0175] The jig and layup were then placed onto a heated press plate, such as a desktop hot press, preheated to about 280° C., and compressed sufficiently for a designated period of at least 5 minutes to create a bond between the first and second coupons of microporous diffusive material and the adhesive film, while avoiding significant bonding of the laminate to the sacrificial layer. The laminate was then removed from the press and allowed to cool to room temperature.

[0176] The resulting laminate was then laser cut to a final size consistent with the laser cutting process of Example 1, except that no offset was cut around the rectangular portion defining the erodible element. The resulting laminate included a bottom microporous diffusive material layer that matched the size and shape of the second layer 9020 shown in Figure 10 and a top microporous diffusive material layer that matched the size and shape of the first layer 9010 shown in Figure 10.

[0177] A fluid conduit formed from silicone tubing was inserted between the non-compressible layers and routed to the interior of the glaucoma drainage device by slightly separating the non-compressible layers and inserting the tubing up to the inner circumference defined by the first and second coupons of microporous diffusive material joined together. The tubing was then secured to the glaucoma drainage device according to known methods.

[0178] Example 3 Hydrophobic ePTFE device assemblies from Examples 1 or 2 were hydrophilically coated as follows: The ePTFE was wetted by delivering approximately 1 ml of 100% isopropyl alcohol directly through the fluid conduits (e.g., silicone tubing) of the device and flushed through the ePTFE reservoir. Approximately 1 ml of deionized water (nominal resistance, approximately 10) was then flushed through the fluid conduits and ePTFE reservoir. 6 Excess alcohol was flushed from the device with 0.5 ohms. Next, about 1 ml of 0.2 wt% aqueous polyvinyl alcohol was flushed directly through the fluid conduits and ePTFE reservoir and allowed to equilibrate for about 10 minutes. About 1 ml of distilled water was flushed through the fluid conduits and ePTFE reservoir. About 1 ml of an aqueous crosslinking solution (2 vol% glutaraldehyde in about 0.3 molar hydrochloric acid) was warmed to about 40° C. and flushed directly through the device and allowed to equilibrate for about 15 minutes. About 2.5 ml of deionized water was flushed through the fluid conduits and ePTFE reservoir. The material was then equilibrated with a beaker of about 40 ml of fresh deionized water.

[0179] The resulting assembly was then dried in an air oven at 115° C. for approximately 10 minutes.

[0180] Example 4 The device from Example 3 was implanted in the superotemporal quadrant in the subconjunctival plane of New Zealand White rabbits and evaluated for survival over a 14-day period. During implantation, a tunnel was created at the limbus using a 25-gauge needle, where a fluid conduit was passed into the anterior chamber. A 0.01% aqueous solution of sodium fluorescein was used to visualize the aqueous humor reservoir. The injected fluorescein is excited by ultraviolet light, emitting strong fluorescence and is easily visible in a darkened environment. Prior to sacrifice, a 0.01% aqueous solution of sodium fluorescein was injected into the anterior chamber of the implanted eye through a 30-gauge needle for approximately 10 minutes at a nominal flow rate of approximately 10 μL / min. At 14 days, a strongly fluorescent reservoir was observed along with a fluorescent conduit emanating from the implanted reservoir area.

[0181] The scope of the invention of this application has been described above generally and with reference to specific examples. It will be apparent to those skilled in the art that various modifications and variations can be made in the examples without departing from the scope of the present disclosure. Similarly, various components discussed in the examples discussed herein can be combined. Thus, the examples are intended to cover modifications and variations within the scope of the present invention. (Aspect) (Aspect 1) a body including a first microporous membrane, a second microporous membrane, a third microporous membrane, and a fourth microporous membrane in a stacked configuration, the second and third microporous membranes being disposed between the first and fourth microporous membranes, and an expandable reservoir being defined between the second and third microporous membranes, wherein the second and third microporous membranes are configured to resist tissue ingrowth, and the first and fourth microporous membranes are configured to permit tissue ingrowth; a fluid conduit having a first end and a second end, the first end fluidly coupled to the reservoir and the second end extending exterior to the body and insertable into a fluid-filled body cavity such that fluid from the fluid-filled body cavity can be transferred to the reservoir; A biological fluid drainage device comprising: (Aspect 2) 2. The device of embodiment 1, wherein the second and third microporous membranes are partially bonded to one another such that portions of the second and third microporous membranes are free to slide relative to one another or separate from one another. (Aspect 3) The device of any one of embodiments 1 or 2, wherein the second and third microporous membranes each have a different permeability than a permeability of each of the first and fourth microporous membranes. (Aspect 4) The device of any one of embodiments 1-3, wherein at least one of the first, second, third and fourth microporous membranes comprises expanded polytetrafluoroethylene. (Aspect 5) The device of any one of the preceding aspects, further comprising a fifth microporous membrane disposed adjacent to the body, the fifth microporous membrane extending between the body and the second end of the fluid conduit. (Aspect 6) The device of embodiment 5, wherein the fifth microporous membrane is configured to permit tissue ingrowth. (Aspect 7) The device of any one of embodiments 5-6, wherein the fifth microporous membrane is attached to the fluid conduit. (Aspect 8) The device of any one of aspects 5 to 7, wherein the fifth microporous membrane is integral with one of the first, second, third or fourth microporous membranes. (Aspect 9) The device of embodiment 8, wherein the fifth microporous membrane and the first microporous membrane are the same microporous membrane. (Aspect 10) The device of any one of aspects 5-9, further comprising a sixth microporous membrane disposed adjacent to the body, the sixth microporous membrane extending between the body and the second end of the fluid conduit. (Aspect 11) 11. The device of embodiment 10, wherein the sixth microporous membrane and the fourth microporous membrane are the same microporous membrane. (Aspect 12) 12. The device of any one of aspects 10-11, wherein the sixth microporous membrane includes perforations sized to accommodate a fluid conduit such that, upon implantation, the fluid conduit can be extended through the perforations into a fluid-filled body cavity. (Aspect 13) 13. The device of any one of aspects 1-12, wherein the first and fourth microporous membranes are configured to remain permeable to the fluid after tissue ingrowth occurs in the first and fourth microporous membranes, respectively. (Aspect 14) 14. The device of any one of embodiments 1-13, wherein the reservoir is configured to expand when the fluid is delivered to the reservoir. (Aspect 15) 15. The device of embodiment 14, wherein the body is configured to adopt a predetermined profile as a result of expansion of the reservoir. (Aspect 16) 16. The device of any one of embodiments 1-15, wherein the first, second, third and fourth microporous membranes each comprise a plurality of pores, wherein the plurality of pores in the second and third microporous membranes are sized to resist tissue ingrowth and the plurality of pores in the first and fourth microporous membranes are sized to permit tissue ingrowth. (Aspect 17) a first proliferative diffusion membrane configured to permit tissue ingrowth; a first constricting diffusion membrane configured to resist tissue ingrowth, the first constricting diffusion membrane coupled to the first proliferative diffusion membrane; a second constricting diffusion membrane configured to resist tissue ingrowth, the second constricting diffusion membrane being bonded to the first constricting diffusion membrane such that a first region of the second constricting diffusion membrane is bonded to the first constricting diffusion membrane and a second region of the second constricting diffusion membrane is unbonded from the first constricting diffusion membrane, the unbonded second region defining an expandable reservoir; a second proliferative diffusion membrane configured to permit tissue ingrowth, the second proliferative diffusion membrane coupled to the second constricting diffusion membrane; An aqueous humor diffusing device comprising: (Aspect 18) The device of embodiment 17, wherein the first and second proliferative diffusion membranes comprise a plurality of pores configured to permit tissue ingrowth, and the first and second constrictive diffusion membranes comprise a plurality of pores configured to resist tissue ingrowth. (Aspect 19) 19. The device of any one of aspects 17 to 18, wherein the first region of the second constricting diffusion membrane is a peripheral region of the second constricting diffusion membrane, the first region of the second constricting diffusion membrane is bonded to the peripheral region of the first constricting diffusion membrane, and the second region of the second constricting diffusion membrane is a region inside the peripheral region of the second constricting diffusion membrane. (Aspect 20) 20. The device of any one of aspects 17-19, further comprising a fluid conduit having a first end and a second end, the first end being in fluid communication with the reservoir and the second end extending away from the first and second constricting diffusion membranes, and insertable into a fluid-filled body cavity such that fluid from the fluid-filled body cavity can move to the reservoir. (Aspect 21) 21. The device of embodiment 20, further comprising a third proliferative diffusion membrane comprising a plurality of pores sized to permit tissue ingrowth, the third proliferative diffusion membrane positioned adjacent to the first proliferative diffusion membrane and extending along the fluid conduit between the first proliferative diffusion membrane and the second end of the fluid conduit. (Aspect 22) 22. The device of embodiment 21, wherein the third proliferative membrane and the first proliferative diffusion membrane are the same proliferative diffusion membrane. (Aspect 23) 23. The device of any one of embodiments 21-22, wherein the third proliferative diffusion membrane is coupled to the fluid conduit. (Aspect 24) 24. The device of any one of aspects 20-23, further comprising a fourth proliferative diffusion membrane comprising a plurality of pores sized to permit tissue ingrowth, the fourth proliferative diffusion membrane positioned adjacent to the second proliferative diffusion membrane and extending along the fluid conduit between the second proliferative diffusion membrane and a second end of the fluid conduit. (Aspect 25) 25. The device of embodiment 24, wherein the fourth proliferative membrane and the second proliferative diffusion membrane are the same proliferative membrane. (Aspect 26) 26. The device of any one of embodiments 24-25, wherein the fourth proliferative diffusion membrane includes perforations sized to accommodate a fluid conduit such that, upon implantation, the fluid conduit can extend through the perforations into a fluid-filled body cavity. (Aspect 27) 27. The device of any one of embodiments 1-26, wherein said fluid-filled body cavity is the anterior chamber of the eye and said fluid is aqueous humor. (Aspect 28) providing a first proliferative diffusion membrane and a second proliferative diffusion membrane; Providing a first constricting diffusion membrane and a second constricting diffusion membrane; bonding the first proliferative diffusion membrane to the first constricting diffusion membrane, bonding the first constricting diffusion membrane to the second constricting diffusion membrane such that a first region of a first interface surface of the second constricting diffusion membrane is bonded to the first constricting diffusion membrane and such that a second region of the first interface surface is not bonded to the first constricting diffusion membrane, and bonding the second proliferative diffusion membrane to the second constricting diffusion membrane, thereby forming an aqueous humor diffusing member; coupling a fluid conduit to the aqueous humor diffusing member such that the fluid conduit is fluidly coupled with the reservoir such that the conduit is operable to deliver drained aqueous humor to the reservoir; Including, wherein the first and second proliferative diffusion membranes are each configured to permit tissue ingrowth; the first and second constricting diffusion membranes are configured to resist tissue ingrowth; the unbonded second region defines an expandable reservoir; A method for forming a glaucoma drainage device. (Aspect 29) The method of embodiment 28, wherein the aqueous humor diffusing member further comprises a third proliferative diffusion membrane configured to allow tissue in-growth, the third proliferative membrane being positioned adjacent to the first proliferative diffusion membrane and extending along the fluid conduit. (Aspect 30) The method of embodiment 29, wherein the aqueous humor diffusing member further comprises a fourth proliferative diffusion membrane configured to allow tissue in-growth, the fourth proliferative diffusion membrane being positioned adjacent to the second proliferative diffusion membrane and extending along the fluid conduit. (Aspect 31) The method of any one of aspects 28-30, further comprising perforating one of the first, second, third, or fourth proliferative diffusion membranes to include a plurality of pores sized to permit tissue ingrowth. (Aspect 32) The third proliferation diffusion film and the first proliferation diffusion film are the same proliferation diffusion film. The method according to any one of items 0 to 31. (Aspect 33) The method according to any one of aspects 30 to 32, wherein the fourth proliferative diffusion membrane and the second proliferative diffusion membrane are the same proliferative diffusion membrane. (Aspect 34) The method of any one of aspects 30 to 33, wherein the fourth proliferative diffusion membrane includes a perforation sized to accommodate a fluid conduit such that, upon implantation, the fluid conduit can extend through the perforation into the anterior chamber.

Claims

1. An implantable biological fluid drainage device for draining fluid from a fluid-filled body cavity, comprising: a body defining a first microporous diffusive material, a second microporous diffusive material bonded to at least a portion of the first microporous diffusive material, an expandable reservoir between the first microporous diffusive material and the second microporous diffusive material, and one or more erodible elements extending externally relative to a first portion of the body and configured to prevent erosion of the conjunctiva of the eye following implantation of the implantable biological fluid drainage device; a fluid conduit having a first end and a second end, the first end fluidly coupled to the expandable reservoir and the second end extending outside the body and insertable into a fluid-filled body cavity such that the fluid from the fluid-filled body cavity can be transferred to the expandable reservoir; An implantable biological fluid drainage device comprising:

2. An implantable biological fluid drainage device as described in claim 1, wherein the first microporous diffusion material includes an in-growth proliferation layer of a first tissue and an in-growth diffusion layer of a first tissue, and the second microporous diffusion material includes an in-growth proliferation layer of a second tissue and an in-growth diffusion layer of a second tissue.

3. The implantable biofluid drainage device of claim 1, wherein the implantable biofluid drainage device is implantable within a pocket formed between the conjunctiva and sclera of the eye, whereby the body is positioned within the pocket and the fluid conduit penetrates the sclera to access the anterior chamber of the eye.

4. An implantable biological fluid drainage device as described in any one of claims 1 to 3, wherein when the device is implanted into the eye, a first of the one or more erosive elements covers the fluid conduit to form a barrier between the fluid conduit and the conjunctiva.

5. An implantable biofluid drainage device as described in any one of claims 1 to 3, wherein the one or more erosive elements are associated with at least one portion of the implantable biofluid drainage device such that the one or more erosive elements are removable from the device.

6. An implantable biological fluid drainage device as described in any one of claims 1 to 3, wherein a portion of the fluid conduit extends from the body to an extended length, and the one or more erosive elements extend along the length of the fluid conduit a distance shorter than the extended length.

7. An implantable biological fluid drainage device as described in any one of claims 1 to 3, wherein the one or more eroding elements have a width greater than or equal to a diameter of the fluid conduit.

8. An implantable biofluid drainage device as described in any one of claims 1 to 3, wherein a width of the one or more eroding elements remains constant in a direction along the length of the one or more eroding elements.

9. An implantable biofluid drainage device as described in any one of claims 1 to 3, wherein the one or more erodible elements are configured to resist abrasion of the surrounding tissue of the device in high wear areas where the fluid conduit may move relative to the one or more erodible elements.

10. An implantable biofluid drainage device as described in any one of claims 1 to 3, wherein the thickness of the one or more erosive elements tapers linearly or nonlinearly along at least one length of the one or more erosive elements and laterally across the one or more erosive elements.

11. An implantable biofluid drainage device as described in any one of claims 1 to 3, wherein the one or more eroding elements are longitudinally spaced from the main body.

12. An implantable biofluid drainage device as described in any one of claims 2 to 3, wherein the one or more eroding elements extend between the fluid conduit and the conjunctiva, and a portion of the one or more eroding elements interfacing with the conjunctiva is configured to promote tissue ingrowth so as to minimize relative motion between the one or more eroding elements and the conjunctiva.

13. The implantable biofluid drainage device of claim 12, wherein the one or more erosion elements are at least one of: a portion of the one or more erosion elements is positioned adjacent to or near a scleral access; and a portion of the fluid conduit extending through the scleral access is positioned adjacent to or near a portion of the fluid conduit.

14. An implantable biofluid drainage device as described in claim 1, wherein the one or more eroding elements include a second eroding element extending along a portion of the fluid conduit so as to form a barrier between the fluid conduit and the sclera of the eye when the biofluid drainage device is implanted in the eye.

15. A method for manufacturing a semiconductor device comprising: one or more erosion elements; a body having 1. An implantable biological fluid drainage device for draining fluid from a fluid-filled body cavity, comprising: the at least one multi-layered microporous diffusive material is arranged to form an expandable reservoir for receiving the fluid from the fluid-filled body cavity; The at least one multi-layer microporous diffusive material comprises: promoting tissue ingrowth on a first side of said material; preventing tissue ingrowth on a second side of said material; and permeating the biological fluid of the fluid-filled body cavity through the fluid-filled body cavity; It is structured as follows: the first side of the material being an outermost layer of the body such that the implantable biological fluid drainage device can be attached to surrounding tissue after implantation; the second side of the material being an innermost layer of the body such that ingrowth of the tissue into the expandable reservoir is prevented; An implantable biological fluid drainage device, wherein the one or more erosion elements configured to prevent erosion of at least a portion of the conjunctiva of the eye after the implantable biological fluid drainage device is implanted extend externally relative to a first portion of the body.

16. An implantable biofluid drainage device as described in claim 15, wherein the first side of the material has a first microstructure and the second side of the material has a second microstructure different from the first microstructure.

17. An implantable biofluid drainage device as described in claim 15 or 16, wherein the implantable biofluid drainage device is implantable within a pocket formed between the conjunctiva and the sclera of the eye such that the one or more erosive elements extend along and therebetween, and a portion of the one or more erosive elements interfacing with the conjunctiva is configured to promote tissue ingrowth so as to minimize relative motion between the one or more erosive elements and the conjunctiva.

18. An implantable biological fluid drainage device as described in any one of claims 15 to 17, further comprising a fluid conduit having a first end and a second end, the first end fluidly coupled to the expandable reservoir and the second end extending outside the body and insertable into a fluid-filled body cavity such that the fluid from the fluid-filled body cavity can move to the reservoir, and a first eroding element of the one or more eroding elements covers the fluid conduit.

19. An implantable biofluid drainage device as described in claim 18, wherein the one or more erosive elements are positioned to form a barrier between the fluid conduit and the conjunctiva when the implantable biofluid drainage device is implanted in the eye.

20. A method of forming an implantable biological fluid drainage device for draining fluid from a fluid-filled body cavity, comprising: Selecting at least one multi-layer microporous diffusive material, promoting tissue ingrowth on a first side of said material; preventing tissue ingrowth on a second side of said material; and permeating the biological fluid of the fluid-filled body cavity through the fluid-filled body cavity; selecting at least one multi-layer microporous diffusive material configured to an expandable reservoir on a first side of the material; one or more erosion elements; disposing the at least one multi-layer microporous diffusive material to form a body defining a Including, the expandable reservoir is configured to receive the fluid from the fluid-filled body cavity; the one or more erosion elements configured to prevent erosion of the conjunctiva of the eye after implantation of the implantable biological fluid drainage device extend externally relative to a first portion of the body; The method, wherein a first side of the material is configured to attach to surrounding tissue after implantation and the second side of the material is configured to prevent tissue ingrowth into the expandable reservoir.